<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Fluphenazine decanoate (depot) and enanthate for schizophrenia - Maayan, N - 2015 | Cochrane Library</title> <meta content="Fluphenazine decanoate (depot) and enanthate for schizophrenia - Maayan, N - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000307.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Fluphenazine decanoate (depot) and enanthate for schizophrenia - Maayan, N - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000307.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000307.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Fluphenazine decanoate (depot) and enanthate for schizophrenia" name="citation_title"/> <meta content="Nicola Maayan" name="citation_author"/> <meta content="Enhance Reviews Ltd" name="citation_author_institution"/> <meta content="Nicola@enhance-reviews.com" name="citation_author_email"/> <meta content="Seema N Quraishi" name="citation_author"/> <meta content="SQ Therapy" name="citation_author_institution"/> <meta content="Anthony David" name="citation_author"/> <meta content="Institute of Psychiatry" name="citation_author_institution"/> <meta content="Aprajita Jayaswal" name="citation_author"/> <meta content="Paras Hospital" name="citation_author_institution"/> <meta content="Maurice Eisenbruch" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="John Rathbone" name="citation_author"/> <meta content="Bond University" name="citation_author_institution"/> <meta content="Rosie Asher" name="citation_author"/> <meta content="Central Office, Cobweb Buildings" name="citation_author_institution"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD000307.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/02/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000307.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000307.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000307.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Antipsychotic Agents [administration &amp; dosage, *therapeutic use]; Delayed‐Action Preparations [administration &amp; dosage, therapeutic use]; Fluphenazine [administration &amp; dosage, *analogs &amp; derivatives, therapeutic use]; Injections, Intramuscular; Randomized Controlled Trials as Topic; Schizophrenia [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000307.pub2&amp;doi=10.1002/14651858.CD000307.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="8ranHhTh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000307\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000307\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000307.pub2",title:"Fluphenazine decanoate (depot) and enanthate for schizophrenia",firstPublishedDate:"Feb 5, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000307.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000307.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000307.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000307.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000307.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000307.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000307.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000307.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000307.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000307.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2825 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000307.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0204"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0077"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-sec-0166"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/appendices#CD000307-sec-0214"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/table_n/CD000307StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/table_n/CD000307StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Fluphenazine decanoate (depot) and enanthate for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nicola Maayan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0003">Seema N Quraishi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0004">Anthony David</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0005">Aprajita Jayaswal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0006">Maurice Eisenbruch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0007">John Rathbone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0008">Rosie Asher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information#CD000307-cr-0009">Clive E Adams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information/en#CD000307-sec-0220">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 February 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000307.pub2">https://doi.org/10.1002/14651858.CD000307.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000307-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000307-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000307-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000307-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000307-abs-0001" lang="en"> <section id="CD000307-sec-0001"> <h3 class="title" id="CD000307-sec-0001">Background</h3> <p>Intramuscular injections (depot preparations) offer an advantage over oral medication for treating schizophrenia by reducing poor compliance. The benefits gained by long‐acting preparations, however, may be offset by a higher incidence of adverse effects. </p> </section> <section id="CD000307-sec-0002"> <h3 class="title" id="CD000307-sec-0002">Objectives</h3> <p>To assess the effects of fluphenazine decanoate and enanthate versus oral anti‐psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes. </p> </section> <section id="CD000307-sec-0003"> <h3 class="title" id="CD000307-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group’s Trials Register (February 2011 and October 16, 2013), which is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. </p> </section> <section id="CD000307-sec-0004"> <h3 class="title" id="CD000307-sec-0004">Selection criteria</h3> <p>We considered all relevant randomised controlled trials (RCTs) focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti‐psychotics or other depot preparations. </p> </section> <section id="CD000307-sec-0005"> <h3 class="title" id="CD000307-sec-0005">Data collection and analysis</h3> <p>We reliably selected, assessed the quality, and extracted data of the included studies. For dichotomous data, we estimated risk ratio (RR) with 95% confidence intervals (CI). Analysis was by intention‐to‐treat. We used the mean difference (MD) for normal continuous data. We excluded continuous data if loss to follow‐up was greater than 50%. Tests of heterogeneity and for publication bias were undertaken. We used a fixed‐effect model for all analyses unless there was high heterogeneity. For this update. we assessed risk of bias of included studies and used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to create a 'Summary of findings' table. </p> </section> <section id="CD000307-sec-0006"> <h3 class="title" id="CD000307-sec-0006">Main results</h3> <p>This review now includes 73 randomised studies, with 4870 participants. Overall, the quality of the evidence is <i>low to very low</i>. </p> <p>Compared with placebo, use of fluphenazine decanoate does not result in any significant differences in death, nor does it reduce relapse over six months to one year, but one longer‐term study found that relapse was significantly reduced in the fluphenazine arm (n = 54, 1 RCT, RR 0.35, CI 0.19 to 0.64, <i>very low quality evidence</i> ). A very similar number of people left the medium‐term studies (six months to one year) early in the fluphenazine decanoate (24%) and placebo (19%) groups, however, a two‐year study significantly favoured fluphenazine decanoate (n = 54, 1 RCT, RR 0.47, CI 0.23 to 0.96, <i>very low quality evidence</i>). No significant differences were found in mental state measured on the Brief Psychiatric Rating Scale (BPRS) or in extrapyramidal adverse effects, although these outcomes were only reported in one small study each. No study comparing fluphenazine decanoate with placebo reported clinically significant changes in global state or hospital admissions. </p> <p>Fluphenazine decanoate does not reduce relapse more than oral neuroleptics in the medium term (n = 419, 6 RCTs, RR 1.46 CI 0.75 to 2.83, <i>very low quality evidence</i> ). A small study found no difference in clinically significant changes in global state. No difference in the number of participants leaving the study early was found between fluphenazine decanoate (17%) and oral neuroleptics (18%), and no significant differences were found in mental state measured on the BPRS. Extrapyramidal adverse effects were significantly less for people receiving fluphenazine decanoate compared with oral neuroleptics (n = 259, 3 RCTs, RR 0.47 CI 0.24 to 0.91, <i>very low quality evidence</i>). No study comparing fluphenazine decanoate with oral neuroleptics reported death or hospital admissions. </p> <p>No significant difference in relapse rates in the medium term between fluphenazine decanoate and fluphenazine enanthate was found (n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32, <i>very low quality evidence</i>), immediate‐ and short‐term studies were also equivocal. One small study reported the number of participants leaving the study early (29% versus 12%) and mental state measured on the BPRS and found no significant difference for either outcome. No significant difference was found in extrapyramidal adverse effects between fluphenazine decanoate and fluphenazine enanthate. No study comparing fluphenazine decanoate with fluphenazine enanthate reported death, clinically significant changes in global state or hospital admissions. </p> </section> <section id="CD000307-sec-0007"> <h3 class="title" id="CD000307-sec-0007">Authors' conclusions</h3> <p>There are more data for fluphenazine decanoate than for the enanthate ester. Both are effective antipsychotic preparations. Fluphenazine decanoate produced fewer movement disorder effects than other oral antipsychotics but data were of low quality, and overall, adverse effect data were equivocal. In the context of trials, there is little advantage of these depots over oral medications in terms of compliance but this is unlikely to be applicable to everyday clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000307-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000307-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000307-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000307-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000307-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000307-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000307-abs-0003" lang="en"> <h3>Depot fluphenazine decanoate and enanthate for schizophrenia</h3> <p>People with schizophrenia often hear voices or see things (hallucinations) and have strange beliefs (delusions). The main treatment for these symptoms of schizophrenia are antipsychotic drugs, which can be taken by mouth (tablet) or by an injection (depot). Fluphenazine was one of the first antipsychotic to be produced in depot form. The depot comes in two forms (decanoate and enanthate). Depot injections are often used for people who refuse or forget to take tablets (showing poor compliance or adherence with medication). Fluphenazine is an older antipsychotic drug that is very effective in the treatment of schizophrenia. However, when compared to newer antipsychotic drugs, fluphenazine may have serious side effects (such as involuntary shaking, tremors, muscle stiffness and the inability to sit still) and is known to lower people’s mood. </p> <p>This review aimed to investigate the effects of fluphenazine (decanoate and enanthate) for schizophrenia. Searches for relevant randomised controlled trials was run in February 2011 and October 16, 2013. Authors could include and extract data from 73 studies with a total of 4870 participants. There were more studies on fluphenazine decanoate than enanthate.The review authors rated the quality of the evidence in the included trials to be low or very low. A long‐term result from only one trial indicated fluphenazine decanoate reduces the rate of relapse when compared with placebo (‘dummy treatment’). Three studies found that fluphenazine decanoate produced fewer general movement disorders than oral antipsychotics. However, other results showed, overall, the effects and outcomes, including adverse effects for fluphenazine (decanoate and enanthate) are similar to other oral and depot antipsychotics. Important outcomes and information about use of services, going into hospital, satisfaction with care and costs were not reported in any study. </p> <p>Depot injections may offer an advantage over tablets (oral medication) in terms of people taking their medication (complying and adhering to treatment). However, this needs to be balanced with the likelihood of serious side effects, such as involuntary shaking, muscle stiffness, the inability to sit still and lowering in people’s mood. Results did not show any strong evidence that depot fluphenazine produced more adverse effects than other antipsychotics. </p> <p>This should be addressed in future large scale and high quality studies.</p> <p>This plain language summary has been written by a consumer Ben Gray from Rethink Mental Illness. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000307-sec-0204" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000307-sec-0204"></div> <h3 class="title" id="CD000307-sec-0205">Implications for practice</h3> <section id="CD000307-sec-0205"> <section id="CD000307-sec-0206"> <h5 class="title">1. For people with schizophrenia</h5> <p>When compared with either placebo or oral neuroleptics, fluphenazine decanoate does not appear to have a clinically important effect in terms of improving relapse rates based on medium‐term (six months to one year) data. Longer‐term data, however, do support the use of fluphenazine decanoate to reduce relapse when compared to placebo, but not when compared to oral neuroleptics. Relapse data for fluphenazine enanthate were limited and no data comparing it with placebo or oral neuroleptics were available. Fluphenazine depot preparations, especially the decanoate, seem equivalent to oral medications and may even cause less adverse effects. </p> </section> <section id="CD000307-sec-0207"> <h5 class="title">2. For clinicians</h5> <p>The data on the effects of fluphenazine decanoate are clearer than for fluphenazine enanthate. Within the highly unusual setting of a randomised trial, the decanoate may have some advantages over the oral antipsychotics. In clinical life there may be greater advantages in terms of compliance. There are no data to support the claim that depots cause more adverse effects than oral preparations. There are also no data to support the use of high doses. </p> </section> <section id="CD000307-sec-0208"> <h5 class="title">3. For managers or policy makers</h5> <p>Studies did not report data relating to service utilisation and care management. Outcomes relating to use of hospitals and services, satisfaction with care and economics were not reported in any study. This deficiency remains and should be addressed in real world randomised studies. </p> </section> </section> <h3 class="title" id="CD000307-sec-0209">Implications for research</h3> <section id="CD000307-sec-0209"> <section id="CD000307-sec-0210"> <h5 class="title">1. General</h5> <p>Trialists involved in future studies should implement the CONSORT statement (<a href="./references#CD000307-bbs2-0328" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285:1987‐91. ">Moher 2001</a>) to ensure that outcomes are more relevant. Inclusion of hospital and services outcomes, satisfaction with care and economic outcomes would provide valuable data for people with schizophrenia, clinicians and policy makers. </p> </section> <section id="CD000307-sec-0211"> <h5 class="title">2. Specific</h5> <p>A recurring failure to report the exact methodology of allocation was evident throughout the included trials. Only five studies stated the randomisation process used; <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a> used a coin‐throwing method, <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a> a randomisation code, <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a> a pre‐arranged prescribing list, and <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a> a randomisation list and <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> allocated to the next available study number. Allocation concealment is essential to ensure that selection bias is kept to a minimum. </p> <p>Only 14 studies described outcome assessors as being blinded to treatment and were rated low risk of bias (<a href="./references#CD000307-bbs2-0003" title="AltamuraAC , CurrySH , MontgomeryS , WilesDH . Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology1985;87:30‐3. ">Altamura 1985</a>; <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a>; <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>; <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a>; <a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a>; <a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>; <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a>; <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a>; <a href="./references#CD000307-bbs2-0055" title="RussellN , LandmarkJ , MerskeyH , TurpinT . A double‐blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry1982;27:593‐6. ">Russell 1982</a>; <a href="./references#CD000307-bbs2-0068" title="VanPraagHM , BreetveldJ , VanMesdag‐ettyH , WesterhuisR , PenA , SchutT . A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria, Neurologia, Neurochirurgia1970;73:165‐75. ">Van Praag 1970</a>; <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a>; <a href="./references#CD000307-bbs2-0071" title="WistedtB , RantaJ . Comparative double‐blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandinavica1983;67:378‐88. ">Wistedt 1983</a>). <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a> and <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a> were open label trials and <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> described using a 'partially‐blinded' method where only outcome assessors were blinded. The remaining studies were of unclear risk of bias as no information on blinding of outcome assessors was provided. Although most studies were stated to be double blind, only 14 studies described outcome assessors as being blinded to treatment and were rated low risk of bias (<a href="./references#CD000307-bbs2-0003" title="AltamuraAC , CurrySH , MontgomeryS , WilesDH . Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology1985;87:30‐3. ">Altamura 1985</a>; <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a>; <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>; <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a>; <a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a>; <a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>; <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a>; <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a>; <a href="./references#CD000307-bbs2-0055" title="RussellN , LandmarkJ , MerskeyH , TurpinT . A double‐blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry1982;27:593‐6. ">Russell 1982</a>; <a href="./references#CD000307-bbs2-0068" title="VanPraagHM , BreetveldJ , VanMesdag‐ettyH , WesterhuisR , PenA , SchutT . A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria, Neurologia, Neurochirurgia1970;73:165‐75. ">Van Praag 1970</a>; <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a>; <a href="./references#CD000307-bbs2-0071" title="WistedtB , RantaJ . Comparative double‐blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandinavica1983;67:378‐88. ">Wistedt 1983</a>). This is an important strategy for avoiding performance and detection bias. <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a> included participants who were unaccounted for after randomisation was undertaken. This study did not specify from which groups this withdrawal had occurred. In 12 trials the number of people who left the study was not reported. It is important to know how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. Studies included both community‐based and hospitalised people but 16 failed to report the setting (<a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a>; <a href="./references#CD000307-bbs2-0017" title="FengL . Double blind controlled trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenia. Chinese Journal of Nervous and Mental Disorders1990;16(5):299. ">Feng 1990</a>; <a href="./references#CD000307-bbs2-0023" title="HranovLG , YanakievN , StefanovS , NikolovaN , YakimovaR . Haloperidol decanoate and fluphenazine decanoate for schizophrenia: a comparative naturalistic medium term study of efficacy and tolerability. 11th Congress of The European College of Neuropsychopharmacology; 1998 Oct 3 ‐ Nov 4; Paris, France. 1998. ">Hranov 1998</a>; <a href="./references#CD000307-bbs2-0025" title="JavedMA , ChaudhryMR . Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Pakistan Journal of Clinical Psychiatry1991;1(2):69‐74. ">Javed 1991</a>; <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a>; <a href="./references#CD000307-bbs2-0035" title="KreismanD , BlumenthalR , BorensteinM , WoernerM , KaneJ , RifkinA , et al. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low‐dose neuroleptics: the family's view. Psychiatry1988;51(1):3‐13. [MEDLINE: 88218101] ">Kreisman 1988</a>; <a href="./references#CD000307-bbs2-0037" title="LehmannE , QuadbeckH , TegelerJ , FararuniM , HeinrichK . Drug‐response differences of high and standard dosage of fluphenazine‐decanoate in relation to schizophrenic symptoms. Pharmakopsychiatrie und Neuropsychopharmakologie1980;13(3):117‐29. ">Lehmann 1980</a>; <a href="./references#CD000307-bbs2-0048" title="McKaneJP , RobinsonADT , WilesDH , McCreadieRG , StirlingGS . Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in‐patients. British Journal of Psychiatry1987;151:333‐6. ">McKane 1987</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0052" title="QuitkinF , RifkinA , KaneJ , Ramos‐LorenziJR , KleinDF . Long‐acting oral vs injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry1978;35:889‐92. ">Quitkin 1978</a>; <a href="./references#CD000307-bbs2-0054" title="RossiA , DiMicheleVD , VolonteMV , CasacchiaM . Therapeutic evaluation of bromperidol decanoate in schizophrenia ‐ a double‐blind comparison vs. Fluphenazine decanoate [Efficacia terapeutica e tollerabilita del Bromperidolo decanoato VS Flufenazina decanoato nel Disturbo Schizofrenico]. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali1990;114(6):1379‐86. ">Rossi 1990</a>; <a href="./references#CD000307-bbs2-0055" title="RussellN , LandmarkJ , MerskeyH , TurpinT . A double‐blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry1982;27:593‐6. ">Russell 1982</a>; <a href="./references#CD000307-bbs2-0056" title="SchlosbergA , ShadmiM . A comparative controlled study of two long‐acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642‐54. ">Schlosberg 1978</a>; <a href="./references#CD000307-bbs2-0057" title="SchneiderSJ , KirbyEJ , ItilTM . Clinical blood chemistry values and long acting phenothiazines. Pharmacopsychitria1981;14:107‐14. ">Schneider 1981</a>; <a href="./references#CD000307-bbs2-0062" title="SharmaSK , JaigirdarSH . A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia. British Journal of Clinical Research1991;2:177‐86. ">Sharma 1991</a>; <a href="./references#CD000307-bbs2-0071" title="WistedtB , RantaJ . Comparative double‐blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandinavica1983;67:378‐88. ">Wistedt 1983</a>). A few studies, all using fluphenazine decanoate as an intervention, involved people in hospital at the beginning of the trial but these people were later discharged into the community (<a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>; <a href="./references#CD000307-bbs2-0014" title="DonlonPT , AxelradAD , TupinJP , ChienC . Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry1976;17(2):369‐76. ">Donlon 1976</a>; <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a>; <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a>; <a href="./references#CD000307-bbs2-0046" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJP . Intermittant pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137:510‐7. ">McCreadie 1980</a>; <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a>; <a href="./references#CD000307-bbs2-0060" title="GelenbergAJ , DollarJC , SchoolerNR , MieskeM , SevereJ , MandelMR . Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Amercian Journal of Psychiatry1979;136(2):217‐9. LevineJ , SchoolerNR , SevereJ , EscobarJ , GelebergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients ater one year of continuous medication: A controlled study. Advanced Biochemical Psychopharmacology1980;24:483‐93. MandelMR , SevereJB , SchoolerNR , GelenbergAJ , MieskeM . Development and prediction of postpsychotic depression in neuroleptic‐treated schizophrenics. Archives of General Psychiatry1982;39:197‐203. SchoolerNR , LevineJ , NIMH‐PRB Collaborative Fluphenazine Study Group. The initiation of long‐term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine. Pharmakopsychiatria1976;9:159‐69. SchoolerNR , LevineJ , SevereJB , BrauzerB , DiMascioA , KlermanGL , et al. Prevention of relapse in schizophrenia ‐ An evaluation of fluphenazine decanoate. Archives of General Psychiatry1980;37:16‐24. ">Schooler 1980</a>; <a href="./references#CD000307-bbs2-0061" title="SchoolerNR , KeithSJ , SeverJB , MatthewsSM , BellackAS , GlickID , et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry1997;54(5):453‐63. ">Schooler 1997</a>; <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>; <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a>). More community‐based studies would be welcome. </p> <p>This review highlights the need for good controlled clinical trials to address the effects of fluphenazine decanoate and fluphenazine enanthate and to assess their clinical suitability in certain situations. Despite the many studies that are in existence, we do think that more studies are required in each category but particularly in the case of fluphenazine enanthate where data were particularly few. We realise that such design needs a great deal of planning but suggest a simple outline in <a href="#CD000307-tbl-0004">Table 1</a>. </p> <div class="table" id="CD000307-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 12 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 300*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Fluphenazine decanoate/enanthate: clinically acceptable dose. N = 150.</p> <p>2. Oral antipsychotic: clinically acceptable dose. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death and all causes of mortality**<br/> Clinical global state ‐ relapse**; clinically significant change in global state**; leaving the study early**<br/> Service utilisation outcomes ‐ hospital admission**, time in hospital.<br/> Adverse effects: extrapyramidal adverse effects**, other adverse effects.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* The number of participants needed to gain sufficient power to highlight about a 10% difference between groups for primary outcome depends on the primary outcome used and the prevalence/magnitude of this outcome. N = 300 is approximately the size of study to detect a 10% difference in improvement with 80% certainty. </p> <p>** Primary outcome</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000307-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000307-sec-0015"></div> <div class="table" id="CD000307-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANOATE<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANOATE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5</b> <br/> (0.25 to 99.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>673 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> <br/> (162 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.24 to 1.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically significant change in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> <br/> (143 to 406) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.3</b> <br/> (0.77 to 2.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> BPRS<br/> Follow‐up: 9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>2.03 lower</b> <br/> (4.51 lower to 0.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ tardive dyskinesia</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>852 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>707 per 1000</b> <br/> (528 to 946) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.62 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment and blinding.<br/> <sup>2</sup> Imprecision: very serious ‐ There were few participants and few events; the confidence intervals are wide.<br/> <sup>3</sup> Publication bias: strongly suspected ‐ Four studies or fewer reported data for this outcome.<br/> <sup>4</sup> Risk of bias: serious ‐ The studies had an unclear risk of bias for randomisation, allocation concealment and blinding of participants.<br/> <sup>5</sup> Inconsistency: very serious ‐ There is very high heterogeneity.<br/> <sup>6</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>7</sup> Risk of bias: very serious ‐ This study had a high risk of bias for incomplete outcome data, and an unclear risk of bias for randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000307-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANOATE<br/> <b>Comparison:</b> ORAL NEUROLEPTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL NEUROLEPTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANOATE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>423 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> <br/> (317 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (0.75 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No clinically important global change</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> <br/> (291 to 659) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.56 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b> <br/> (134 to 230) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.73 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> BPRS endpoint score<br/> Follow‐up: (longer term ‐ more than 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0.75 lower</b> <br/> (5.75 lower to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ general</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> <br/> (33 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.24 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies also reported equivocal results for akathisia, needing anticholinergic drugs, tardive dyskinesia, tremor, and symptoms on the Simpson Angus scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding. One study had a high risk of bias for incomplete outcome data.<br/> <sup>2</sup> Inconsistency: serious ‐ There is high heterogeneity.<br/> <sup>3</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>4</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment, blinding and incomplete outcome data.<br/> <sup>5</sup> Publication bias: strongly suspected ‐ Three studies or fewer reported data for this outcome.<br/> <sup>6</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding, although one study had a low risk of bias for blinding of participants. One study had a high risk of bias for incomplete outcome data.<br/> <sup>7</sup> Publication bias: undetected ‐ It seems that larger trials have not been performed, see <a href="./full#CD000307-fig-0001">Figure 1</a>. </p> <p><sup>8</sup>Risk of bias: very serious ‐ This study had a high risk of bias for blinding as it is an open label study. It has an unclear risk of bias for randomisation and allocation concealment.<br/> <sup>9</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="figure" id="CD000307-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS, outcome: 2.4 Leaving the study early." data-id="CD000307-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS, outcome: 2.4 Leaving the study early. </p> </div> </div> </div> <div class="table" id="CD000307-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANAOTE<br/> <b>Comparison:</b> FLUPHENAZINE ENANTHATE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE ENANTHATE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANAOTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> <br/> (85 to 998) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/> (0.71 to 8.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinically significant change in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> <br/> (85 to 998) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/> (0.71 to 8.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental State</b> <br/> BPRS<br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0 higher</b> <br/> (3.93 lower to 3.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ general</b> <br/> Follow‐up: short term (6 weeks to 5 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>614 per 1000</b> <br/> (425 to 883) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/> (0.79 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies also reported equivocal results for Parkinsonism, akathisia and needing anticholinergic drugs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment and blinding.<br/> <sup>2</sup> Imprecision: very serious ‐ There were few participants and few events; the confidence intervals are wide.<br/> <sup>3</sup> Publication bias: strongly suspected ‐ Fewer than three studies reported data for this outcome.<br/> <sup>4</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>5</sup> Risk of bias: serious ‐ The studies had an unclear risk of bias for randomisation and blinding of outcome assessors. One was low risk of bias for allocation concealment and the other for blinding of participants. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000307-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000307-sec-0016"></div> <section id="CD000307-sec-0017"> <h3 class="title" id="CD000307-sec-0017">Description of the condition</h3> <p>One in every 10,000 people per year are diagnosed with schizophrenia, with a lifetime prevalence of about 1% (<a href="./references#CD000307-bbs2-0315" title="JablenskyA , SartoriusN , ErnbergG , AnkerM , KortenA , CooperJ , et al.A World Health Organization ten‐country study. Schizophrenia: manifestations, incidence and course indifferent cultures. Psychological Medicine Monograph Supplement1992;20:1‐97. ">Jablensky 1992</a>). It often runs a chronic course with acute exacerbations and often partial remissions. The neuroleptic group of drugs is the mainstay treatment for this illness (<a href="./references#CD000307-bbs2-0296" title="DenckerSJ , LeppM , MalmU . Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatria Scandinavica1980;61(supp 279):64‐76. ">Dencker 1980</a>). These are generally regarded as highly effective, especially in controlling such symptoms as hallucinations and fixed false beliefs (delusions) (<a href="./references#CD000307-bbs2-0316" title="KaneJM , WoernerM , SarantakosS . Depot neuroleptics: A comparison review of standard, intermediate and low‐dose regimens. Journal of Clinical Psychiatry1986;47(suppl 5):30‐3. ">Kane 1986</a>). They seem to reduce the risk of acute relapse. </p> <p>Anti‐psychotic drugs are usually given orally (<a href="./references#CD000307-bbs2-0281" title="Aaes‐JorgensonA . Pharmacokinetics of oral and depot neuroleptics‐Clinical relevance. Symposium Espo, 1985 Feb 1. ">Aaes‐Jorgenson 1985</a>), but compliance with medication given by this route may be difficult to quantify. Problems with treatment adherence are common throughout medicine (<a href="./references#CD000307-bbs2-0308" title="HaynesRB , TaylorWD , Sackett DL(eds) . Compliance in health care. Baltimore: John Hopkins University Press, 1979. ">Haynes 1979</a>). Those who suffer from long‐term illness such as schizophrenia are less likely to take medication regularly if experiencing adverse effects (<a href="./references#CD000307-bbs2-0317" title="KaneJM , AgugliaE , Carlo AltamuraA , GuiterrezJLA , BrunelloN , FleischhackerWW , et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropschopharmacology1998;8:55‐66. ">Kane 1998</a>), or if they experience cognitive impairments (<a href="./references#CD000307-bbs2-0292" title="DavidAS , Cutting JC(Eds.) . The Neuropsychology of Schizophrenia. Hove, E. Sussck: Lawrence Erlbaum Assoc, 1994. ">David 1994</a>) and erosion of insight. The development of depot injections in the 1960s and initial clinical trials (<a href="./references#CD000307-bbs2-0312" title="HirschSR , GaindR , RohdePD . Outpatient maintenance of chronic schizophrenic patients with long‐acting fluphenazine: double‐blind placebo controlled trial. British Medical Journal1973;1:633‐7. ">Hirsch 1973b</a>) gave rise to extensive use of depots as a means of long‐term maintenance treatment. </p> </section> <section id="CD000307-sec-0018"> <h3 class="title" id="CD000307-sec-0018">Description of the intervention</h3> <p>Fluphenazine was one of the first oral antipsychotics to be produced in a depot form. Two forms of the depot, a decanoate (Modecate) and an enanthate (Moditen) are available. The decanoate is more commonly prescribed (<a href="./references#CD000307-bbs2-0325" title="MarderSR , VanPuttenT , AravagiriM . Fluphenazine plasma levels and clinical response. Psychopharmacology Bulletin1990;26:256‐8. ">Marder 1990</a>) and lasts about four to six weeks in the body, while a single dose of the enanthate is shorter acting (one to three weeks). Evidence also suggests that the decanoate may produce slightly less adverse effects than its enanthate counterpart (<a href="./references#CD000307-bbs2-0320" title="KurlandAA , DimBM , OlssenJE . The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics. Diseases of the Nervous System1970;31(Supp9):18‐23. ">Kurland 1970</a>). However, in comparison with newer depot formulations fluphenazine decanoate has been reported to cause greater extrapyramidal adverse effects (<a href="./references#CD000307-bbs2-0192" title="KnightsA , OkashaMS , SalihMA , HirschSR . Depressive and extrapyramidal symptoms and clinical effects: A trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out‐patients. British Journal of Psychiatry1979;135:515‐23. ">Knights 1979</a>) and to significantly lower mood (<a href="./references#CD000307-bbs2-0294" title="DeAlarconR , CarneyMW . Severe depressive mood changes following slow‐release intramuscular fluphenazine injection. British Medical Journal1969;3(670):564‐7. ">De Alarcon 1969a</a>). </p> </section> <section id="CD000307-sec-0019"> <h3 class="title" id="CD000307-sec-0019">How the intervention might work</h3> <p>Depots mainly consist of an ester of the active drug held in an oily suspension. This is injected intramuscularly and is slowly released. Depots may be given every one to six weeks. Individuals may be maintained in the community with regular injections administered by community psychiatric nurses, sometimes in clinics set up for this purpose (<a href="./references#CD000307-bbs2-0287" title="BarnesTRE , CursonDA . Long term depot antipsychotics. A risk benefit assessment. Drug Safety1994;10(6):464‐79. ">Barnes 1994</a>). The use of depots eradicates covert non‐compliance. </p> </section> <section id="CD000307-sec-0020"> <h3 class="title" id="CD000307-sec-0020">Why it is important to do this review</h3> <p>A systematic review undertaken over a decade ago suggested that, for those with serious mental illness, stopping anti‐psychotics resulted in 58% of people relapsing, whereas only 16% of those who were still on the drugs became acutely ill within a one‐year period (<a href="./references#CD000307-bbs2-0293" title="DavisJM , AndriukatisS . The natural course of schizophrenia and effective maintenance drug therapy. Journal of Clinical Psychopharmacology1986;6(1Suppl):2S‐10S. ">Davis 1986</a>). Evidence also points to the fact that experiencing a relapse of schizophrenia lowers a person's level of social functioning and quality of life (<a href="./references#CD000307-bbs2-0116" title="CursonDA , BarnesTRE , BamberRW , PlattSD , HirschSR , DuffyJC . Long term depot maintenance of chronic schizophrenic out‐patients: The seven year follow‐up of the Medical Reseach Council fluphenazine/placebo trial. British Journal of Psychiatry1985;146:464‐80. ">Curson 1985</a>). Relapse prevention has also enormous financial implications. For example, within the UK, a Department of Health burden of disease analysis in 1996 indicated that schizophrenia accounted for 5.4% of all National Heath Service inpatient expenditure, placing it behind only learning disability and stroke in magnitude (<a href="./references#CD000307-bbs2-0299" title="Department of Health. Burdens of Disease: a Discussion Document. Department of Health. NHS Executive1996. ">DoH 1996</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000307-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000307-sec-0021"></div> <p>To assess the effects of fluphenazine decanoate and enanthate versus oral anti‐psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000307-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000307-sec-0022"></div> <section id="CD000307-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000307-sec-0024"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials. If a trial had been described as 'double blind' but implied randomisation, we would have included such trials in a sensitivity analysis (see <a href="#CD000307-sec-0070">Sensitivity analysis</a>). If their inclusion did not result in a substantive difference, they would have remained in the analyses. If their inclusion did result in statistically significant differences, we would not have added the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory.<br/> <br/> We excluded quasi‐randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments with fluphenazine decanoate or fluphenazine enanthate, we only included data if the adjunct treatment was evenly distributed between groups and it was only the fluphenazine decanoate or fluphenazine enanthate that was randomised. </p> </section> <section id="CD000307-sec-0025"> <h4 class="title">Types of participants</h4> <p>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis. </p> <p>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible so proposed to clearly highlight the current clinical state (acute, early post‐acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD000307-sec-0026"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD000307-list-0001"> <li> <p>Fluphenazine decanoate: any dose.</p> </li> <li> <p>Fluphenazine enanthate: any dose.</p> </li> <li> <p>Oral anti‐psychotics (with the exception of fluphenazine hydrochloride): any dose.</p> </li> <li> <p>Other depot preparations: any dose.</p> </li> <li> <p>Placebo.</p> </li> </ol> </p> </section> <section id="CD000307-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>Outcomes were grouped into immediate (zero to five weeks), short term (six weeks to five months), medium term (six months to one year) and longer term (over 12 months) </p> <section id="CD000307-sec-0028"> <h5 class="title">Primary outcomes</h5> <p><b>1. Death and all causes of mortality</b> </p> <p><b>2. Clinical global state</b> <br/> 2.1 Relapse<br/> 2.2 Clinically significant change in global state ‐ as defined by each of the studies </p> <p><b>3. Leaving the study early</b> </p> <p><b>4. Service utilisation outcomes</b> <br/> 4.1 Hospital admission </p> </section> <section id="CD000307-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p><b>1. Clinical global state</b> <br/> 1.1 Mean score/change in global state </p> <p><b>2. Behaviour*</b> </p> <p><b>3. Mental state</b><br/> 3.1 Clinically significant change in psychotic symptoms ‐ as defined by each of the studies<br/> 3.2 Mean score/change in psychotic symptoms<br/> 3.3 Clinically significant change in positive symptoms ‐ as defined by each of the studies<br/> 3.4 Mean score/change in positive symptoms<br/> 3.5 Clinically significant response in negative symptoms ‐ as defined by each of the studies<br/> 3.6 Mean score/change in negative symptoms </p> <p><b>4. Extrapyramidal adverse effects</b><br/> 4.1 Incidence of use of antiparkinson drugs<br/> 4.2 Clinically significant extrapyramidal adverse effects ‐ as defined by each of the studies<br/> 4.3 Mean score/change in extrapyramidal adverse effects </p> <p><b>5. Other adverse effects, general and specific</b> </p> <p><b>6. Service utilisation outcomes</b><br/> 6.1 Days in hospital </p> <p><b>7. Economic outcomes</b> </p> <p><b>8. Quality of life/satisfaction with care for either recipients of care or carers</b><br/> 8.1 Significant change in quality of life/satisfaction ‐ as defined by each of the studies<br/> 8.2 Mean score/change in quality of life/satisfaction. </p> <p><b>9. 'Summary of findings' table</b> </p> <p>We used the GRADE approach to interpret findings (<a href="./references#CD000307-bbs2-0330" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>) and used <a href="http://www.ims.cochrane.org/reviewmanger/gradepro" target="_blank">GRADE</a> profiler to import data from RevMan 5 (<a href="http://www.ims.cochrane.org/reviewmanager" target="_blank">Review Manager</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient‐care and decision making. We selected the following main outcomes at medium‐term follow‐up for inclusion in the 'Summary of findings' table. </p> <p> <ol id="CD000307-list-0002"> <li> <p>Death and all causes of mortality</p> </li> <li> <p>Relapse</p> </li> <li> <p>Clinically significant change in global state</p> </li> <li> <p>Hospital admission</p> </li> <li> <p>Leaving the study early</p> </li> <li> <p>Mental state</p> </li> <li> <p>Extrapyramidal adverse effects</p> </li> </ol> </p> <p>* additional outcome</p> </section> </section> </section> <section id="CD000307-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000307-sec-0031"> <h4 class="title">Electronic searches</h4> <section id="CD000307-sec-0032"> <h5 class="title">1. Cochrane Schizophrenia Group’s Trials Register</h5> <p>The Trials Search Co‐ordinator (TSC) searched the Cochrane Schizophrenia Group’s Registry of Trials (February 2011 and October 16, 2013) using the following search strategies which have been developed based on literature review and consulting the authors of the review: </p> <p>((*anaten* or *Cardilac* or *Cenilene* or *dapotum* or *Decafen* or *decazate* or *Decentan* or *enanthate* or *eutimox* or *Fludeca* or *flufen* or *flunanthate* or *fluphen* or *Idazoxan* or *Lyogen * or *lyoridin* or *Mirenil* or *modec* or *moditen* or *Omca* or *Oxyprothepin* or *Pacinol* or *Permitil* or *phenathiazine* or *piperazine* or *prolixin* or *Prolongatum* or *Rx 781094* or *sediten* or *selecten* or *Sevinol* or *sinqualone* or *siqualone* or *trancin*) and (*decanoat* or *depot* or *long?act* or *delayed?act*)):ti,ab,kw of REFERENCE or (*fluphenaz* and *depot*):sin of STUDY </p> <p>The Cochrane Schizophrenia Group’s Registry of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, EMBASE, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, see <a href="./appendices#CD000307-sec-0215">Appendix 1</a>. </p> </section> </section> <section id="CD000307-sec-0033"> <h4 class="title">Searching other resources</h4> <p><b>1. Reference searching</b> <br/> We also inspected the references of all identified trials for more studies. We sought each of the included studies as a citation on the SCISEARCH database. Then we inspected reports of articles that had cited these studies in order to identify further trials. </p> <p><b>2. Personal contact</b> <br/> We tried to contact the first author of each included study for information regarding unpublished trials. We contacted companies producing depots and made requests for reports of published and unpublished trials. Where authors responded, this is noted in the <a href="./references#CD000307-sec-0226" title="">Characteristics of included studies</a>. </p> </section> </section> <section id="CD000307-sec-0034"> <h3 class="title" id="CD000307-sec-0034">Data collection and analysis</h3> <p>This is an update of the original review (<a href="./references#CD000307-bbs2-0334" title="DavidA , AdamsCE , EisenbruchM , QuraishiSN , RathboneJ . Depot fluphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews2004, Issue 2. [DOI: 10.1002/14651858.CD000307] ">David 2004</a>). Methods used in data collection and analysis for this update are below, for previous methods please see <a href="./appendices#CD000307-sec-0216">Appendix 2</a>. </p> <section id="CD000307-sec-0035"> <h4 class="title">Selection of studies</h4> <p>For the update screening, two members of the Enhance Reviews team (NM and RA) independently inspected citations from the 2011 and 2013 searches and identified relevant abstracts. A random 20% sample was independently re‐inspected by a senior researcher in the team to ensure reliability. Where disputes arose, the full report was acquired for more detailed scrutiny. If citations met inclusion criteria, we obtained full reports of the papers for more detailed inspection. Again, a random 20% of reports were re‐inspected by a senior researcher in the team in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification. </p> </section> <section id="CD000307-sec-0036"> <h4 class="title">Data extraction and management</h4> <section id="CD000307-sec-0037"> <h5 class="title">1. Extraction</h5> <p>For this update, review author NM extracted data from included studies and RA checked the data. We extracted data presented only in graphs and figures whenever possible, but only included if two review authors had the same results. When further information was necessary, we contacted authors of studies in order to obtain missing data or for clarification. No studies were multi‐centre; had there been, we would have extracted data relevant to each component centre separately where possible. </p> </section> <section id="CD000307-sec-0038"> <h5 class="title">2. Management</h5> <section id="CD000307-sec-0039"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD000307-sec-0040"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:<br/> a. the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD000307-bbs2-0327" title="MarshallM , LockwoodA , BradleyC , AdamsCE , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>); and<br/> b. the measuring instrument has not been written or modified by one of the trialists for that particular trial. </p> </section> <section id="CD000307-sec-0041"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages to both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>, Chapter 9.4.5.2). </p> </section> <section id="CD000307-sec-0042"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD000307-bbs2-0283" title="AltmanDG , BlandJM . Statistics Notes: Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>)); c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), <a href="./references#CD000307-bbs2-0318" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S‐S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and these rules can be applied. We entered skewed endpoint data from studies of fewer than 200 participants in 'other tables' within the data and analyses section rather than into a statistical analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we entered such data from studies with over 200 participants into syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not; we entered skewed change data into analyses. </p> </section> <section id="CD000307-sec-0043"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD000307-sec-0044"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD000307-bbs2-0329" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD000307-bbs2-0318" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD000307-bbs2-0321" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005</a>; <a href="./references#CD000307-bbs2-0322" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD000307-sec-0045"> <h6 class="title">2.7 Direction of graphs</h6> <p>We entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for fluphenazine esters. </p> </section> </section> </section> <section id="CD000307-sec-0046"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For this 2013 update, the Enhanced Reviews team used the criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) to assess trial quality. This new set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>We have noted the level of risk of bias in both the text of the review and in the <a href="./full#CD000307-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD000307-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD000307-tbl-0003">summary of findings Table 3</a>. </p> </section> <section id="CD000307-sec-0047"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000307-sec-0048"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<a href="./references#CD000307-bbs2-0289" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD000307-bbs2-0295" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The Number Needed to Treat/Harm (NNT/H) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD000307-bbs2-0314" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). Therefore, we did not present NNTs. </p> </section> <section id="CD000307-sec-0049"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, we estimated mean difference (MD) between groups. We prefer not to calculate effect size measures (standardised mean difference SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. Where trials reported mean data adjusted for baseline and standard error using ANCOVA, we entered this data using the generic inverse variance according to section 9.4.5.2 of the <i>Cochrane Handbook</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). </p> </section> </section> <section id="CD000307-sec-0050"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000307-sec-0051"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD000307-bbs2-0298" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD000307-bbs2-0288" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD000307-bbs2-0306" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>None of the trials we included were cluster trials. Had there been, where clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we would seek to contact first authors of studies to obtain intra‐class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD000307-bbs2-0306" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m‐1)*ICC] (<a href="./references#CD000307-bbs2-0300" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported we would have assumed it to be 0.1 (<a href="./references#CD000307-bbs2-0332" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique. </p> </section> <section id="CD000307-sec-0052"> <h5 class="title">2. Cross‐over trials</h5> <p>Some included studies used a cross‐over design. A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD000307-bbs2-0302" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD000307-sec-0053"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>For the included studies with more than two treatment arms, we presented the additional treatment arms in comparisons. Where data were binary, we simply added these and combined them within the two‐by‐two table. Where data were continuous we combined data following the formula in section 7.7.3.8 (Combining groups) of the <i>Handbook</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD000307-sec-0054"> <h4 class="title">Dealing with missing data</h4> <section id="CD000307-sec-0055"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD000307-bbs2-0333" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, where more than 30% of those randomised were lost to follow‐up by six months, or 50% of data by beyond that time be unaccounted for, we did not reproduce these data or use them within analyses. </p> </section> <section id="CD000307-sec-0056"> <h5 class="title">2. Continuous</h5> <section id="CD000307-sec-0057"> <h6 class="title">2.1 Attrition</h6> <p>In the case where attrition for a continuous outcome was between 0% and 50% and completer‐only data were reported, we reproduced these. </p> </section> <section id="CD000307-sec-0058"> <h6 class="title">2.2 Standard deviations</h6> <p>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or T value available for differences in mean, we can calculate them according to the rules described in the <i>Handbook</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>): When only the SE is reported, SDs are calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <i>Handbook</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>) present detailed formulae for estimating SDs from P values, T or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we would calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD000307-bbs2-0305" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> </section> </section> <section id="CD000307-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD000307-sec-0060"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these. </p> </section> <section id="CD000307-sec-0061"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these. </p> </section> <section id="CD000307-sec-0062"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD000307-sec-0063"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD000307-sec-0064"> <h6 class="title">3.2 Employing the I<sup>2</sup> statistic </h6> <p>We investigated heterogeneity between studies by considering the I<sup>2</sup> method alongside the Chi<sup>2</sup> P value. The I<sup>2</sup> provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD000307-bbs2-0310" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). The importance of the observed value of I<sup>2</sup> depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<sup>2</sup> test, or a confidence interval for I<sup>2</sup>). an I<sup>2</sup> estimate greater than or equal to around 50% accompanied by a statistically significant Chi<sup>2</sup> statistic was interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). When substantial levels of heterogeneity were found in the primary outcome, we explored reasons for heterogeneity (see <a href="#CD000307-sec-0067">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD000307-sec-0065"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD000307-bbs2-0301" title="EggerM , Davey‐SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Handbook</i> (<a href="./references#CD000307-bbs2-0311" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD000307-sec-0066"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies, even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses, unless there was high heterogeneity (see <a href="#CD000307-sec-0059">Assessment of heterogeneity</a>), in which case we used the random‐effects model. The reader is, however, able to choose to inspect the data using the random‐effects model. </p> </section> <section id="CD000307-sec-0067"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD000307-sec-0068"> <h5 class="title">1. Subgroup analyses ‐ only primary outcomes</h5> <section id="CD000307-sec-0069"> <h6 class="title">1.1 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of fluphenazine esters for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. In order to do subgroup analyses, we needed to have at least six studies for an outcome. </p> </section> </section> </section> <section id="CD000307-sec-0070"> <h4 class="title">Sensitivity analysis</h4> <p>We aimed to apply all sensitivity analyses to the primary outcomes of this review, again, if there were at least six studies with data for a particular outcome. </p> <section id="CD000307-sec-0071"> <h5 class="title">1. Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes, we would have included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have entered all data from these studies. </p> </section> <section id="CD000307-sec-0072"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>If assumptions had to be made regarding people lost to follow‐up and missing SDs data (see <a href="#CD000307-sec-0054">Dealing with missing data</a>), we would have compared the findings on primary outcomes when we used our assumption compared with completer data only. We would have undertaken a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we would have reported results and discussed them, but continued to employ our assumption. </p> </section> <section id="CD000307-sec-0073"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available): allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD000307-sec-0074"> <h5 class="title">4. Imputed values</h5> <p>If we had included cluster trials, we also would have completed a sensitivity analysis to assess the effects of including data from trials if we needed to use imputed values for ICC in calculating the design effect in cluster randomised trials. </p> <p>If we had noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but would have presented them separately. </p> </section> <section id="CD000307-sec-0075"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>We synthesised data using a fixed‐effect model.</p> </section> <section id="CD000307-sec-0076"> <h5 class="title">6. Dose</h5> <p>We tested the sensitivity of the primary outcomes as to whether high (250 mg) or low (25 mg) dose of fluphenazine decanoate was used or whether the trials used an intermediate/high (0.5 mg) or low (0.25 mg) dose of fluphenazine enanthate. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000307-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000307-sec-0077"></div> <section id="CD000307-sec-0078"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD000307-sec-0226" title="">Characteristics of included studies</a>, <a href="./references#CD000307-sec-0227" title="">Characteristics of excluded studies</a> and <a href="./references#CD000307-sec-0228" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD000307-sec-0079"> <h4 class="title">Results of the search</h4> <p>The original search yielded 982 citations using the search strategy. Two hundred and forty‐eight citations were related to fluphenazine decanoate or enanthate but only 62 referred to controlled clinical trials (all published in journals). The review was also updated in May 2002, a further electronic search yielded 247 citations from which we obtained 124 articles for further inspection. </p> <p>The 2013 update search identified 44 potential studies and after screening we added four new studies (<a href="./references#CD000307-bbs2-0027" title="JuH , CongZ , DengP . A control study on using pipothiazine palmitate to treat schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(1):24‐5. ">Ju 2000</a>; <a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>; <a href="./references#CD000307-bbs2-0033" title="KhazaeiH , HabibiF , PourafkariN . The effect of fluphenazine decanoate every 2 weeks versus 6 weeks in the treatment of schizophrenia and schizoaffective disorders. Iranian Journal of Psychiatry and Clinical Psychology2003;8(4):11‐5. KhazaieH , ShakeriJ . Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate. Archives of Iranian Medicine2005;8(2):109‐14. ">Khazaie 2005</a>; <a href="./references#CD000307-bbs2-0063" title="ShenoyRS , SadlerSG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141‐5. ">Shenoy 1981</a>) to the included studies. Two previously included studies, <a href="./references#CD000307-bbs2-0324" title="MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1984</a> and <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a>, were found to include the same participants, and so were added as the same study. The total number of included studies is now 73 randomised controlled trials with a total of 90 reports. </p> <p>For overall screening from the three searches see <a href="#CD000307-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD000307-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD000307-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD000307-sec-0080"> <h4 class="title">Included studies</h4> <section id="CD000307-sec-0081"> <h5 class="title">1. Length of trials</h5> <p>The duration for all the studies ranged between two weeks (<a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>) to three years (<a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>). </p> </section> <section id="CD000307-sec-0082"> <h5 class="title">2. Participants</h5> <p>The diagnoses of all participants were schizophrenia or some other similar psychotic disorder. Most of the studies included people of both sexes, although seven studies (<a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a>; <a href="./references#CD000307-bbs2-0004" title="AsarnowRE , MarderSR , MintzJ , VanPuttenT , ZimmermanKE . Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information‐processing skills. Archives of General Psychiatry1988;45:822‐7. ">Asarnow 1988</a>; <a href="./references#CD000307-bbs2-0036" title="KurlandAA , RichardsonJH . A comparative study of two long acting phenothiazine preparations, fluphenazine enanthate and fluphenazine decanoate. Psychopharmacologia (Berl)1966;9:320‐7. ">Kurland 1966</a>; <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a>; <a href="./references#CD000307-bbs2-0046" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJP . Intermittant pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137:510‐7. ">McCreadie 1980</a>; <a href="./references#CD000307-bbs2-0047" title="McCreadieR , MackieM , MorrisonD , KiddJ . Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1982;140:280‐6. ">McCreadie 1982</a>) included only men and 16 trials failed to mention the sex of participants. Ages ranged between 13 and 81 years, but most people were in the 18 to 65 age range. Most trial participants had long histories of schizophrenia, although many studies (n = 44) failed to mention the length of time people had been ill. Researchers frequently used operational criteria for diagnoses (RDC, Schneider's first rank symptoms, Hay &amp; Forrest 1972 criteria, PSE, Kraepelinian, ICD ‐9, DSM‐II/III, Bleuler's criteria, <a href="./references#CD000307-bbs2-0304" title="FeighnerJP , RobinsE , GuzeS , WoodruffRA , WinokurG , MunozR . Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry1972;26:57‐62. ">Feighner 1972</a> criteria, Chinese Classification of Mental Disorders and Huangshan council schizophrenia standard), although 31 (43%) trials did not specify which diagnostic criteria were used. </p> </section> <section id="CD000307-sec-0083"> <h5 class="title">3. Setting</h5> <p>The trials were both community‐ and hospital‐based. People in two studies (<a href="./references#CD000307-bbs2-0060" title="GelenbergAJ , DollarJC , SchoolerNR , MieskeM , SevereJ , MandelMR . Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Amercian Journal of Psychiatry1979;136(2):217‐9. LevineJ , SchoolerNR , SevereJ , EscobarJ , GelebergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients ater one year of continuous medication: A controlled study. Advanced Biochemical Psychopharmacology1980;24:483‐93. MandelMR , SevereJB , SchoolerNR , GelenbergAJ , MieskeM . Development and prediction of postpsychotic depression in neuroleptic‐treated schizophrenics. Archives of General Psychiatry1982;39:197‐203. SchoolerNR , LevineJ , NIMH‐PRB Collaborative Fluphenazine Study Group. The initiation of long‐term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine. Pharmakopsychiatria1976;9:159‐69. SchoolerNR , LevineJ , SevereJB , BrauzerB , DiMascioA , KlermanGL , et al. Prevention of relapse in schizophrenia ‐ An evaluation of fluphenazine decanoate. Archives of General Psychiatry1980;37:16‐24. ">Schooler 1980</a>; <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a>) were given the first two injections whilst in hospital and after which medication continued to be administered in the community. Both <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a> and <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a> studied people initially in a hospital setting followed by a continuation in the community. Several studies involved people from both hospital and community settings (<a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>; <a href="./references#CD000307-bbs2-0014" title="DonlonPT , AxelradAD , TupinJP , ChienC . Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry1976;17(2):369‐76. ">Donlon 1976</a>; <a href="./references#CD000307-bbs2-0030" title="KanenoS , OhkumaT , YamashitaI , MoriA , YagiG , KudoY , et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Rinsho Hyoka (Clinical Evaluation)1991;19(1):15‐45. [MEDLINE: 70166858] ">Kaneno 1991</a>; <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a>; <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a>; <a href="./references#CD000307-bbs2-0046" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJP . Intermittant pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137:510‐7. ">McCreadie 1980</a>; <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a>; <a href="./references#CD000307-bbs2-0061" title="SchoolerNR , KeithSJ , SeverJB , MatthewsSM , BellackAS , GlickID , et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry1997;54(5):453‐63. ">Schooler 1997</a>; <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>). A surprisingly large number (11) of studies did not mention the setting used (<a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a>; <a href="./references#CD000307-bbs2-0025" title="JavedMA , ChaudhryMR . Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Pakistan Journal of Clinical Psychiatry1991;1(2):69‐74. ">Javed 1991</a>; <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a>; <a href="./references#CD000307-bbs2-0048" title="McKaneJP , RobinsonADT , WilesDH , McCreadieRG , StirlingGS . Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in‐patients. British Journal of Psychiatry1987;151:333‐6. ">McKane 1987</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0052" title="QuitkinF , RifkinA , KaneJ , Ramos‐LorenziJR , KleinDF . Long‐acting oral vs injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry1978;35:889‐92. ">Quitkin 1978</a>; <a href="./references#CD000307-bbs2-0055" title="RussellN , LandmarkJ , MerskeyH , TurpinT . A double‐blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry1982;27:593‐6. ">Russell 1982</a>; <a href="./references#CD000307-bbs2-0057" title="SchneiderSJ , KirbyEJ , ItilTM . Clinical blood chemistry values and long acting phenothiazines. Pharmacopsychitria1981;14:107‐14. ">Schneider 1981</a>; <a href="./references#CD000307-bbs2-0056" title="SchlosbergA , ShadmiM . A comparative controlled study of two long‐acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642‐54. ">Schlosberg 1978</a>; <a href="./references#CD000307-bbs2-0062" title="SharmaSK , JaigirdarSH . A comparison of fluphenazine decanoate and haloperidol decanoate in chronic schizophrenia. British Journal of Clinical Research1991;2:177‐86. ">Sharma 1991</a>; <a href="./references#CD000307-bbs2-0071" title="WistedtB , RantaJ . Comparative double‐blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandinavica1983;67:378‐88. ">Wistedt 1983</a>). Thirty‐one trials were conducted in North America and another 29 in Europe, 10 in Asia, one in Africa; and two did not report the country. </p> </section> <section id="CD000307-sec-0084"> <h5 class="title">4. Study size</h5> <p>The largest study was by <a href="./references#CD000307-bbs2-0061" title="SchoolerNR , KeithSJ , SeverJB , MatthewsSM , BellackAS , GlickID , et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Archives of General Psychiatry1997;54(5):453‐63. ">Schooler 1997</a> who randomised 313 people, whereas <a href="./references#CD000307-bbs2-0003" title="AltamuraAC , CurrySH , MontgomeryS , WilesDH . Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology1985;87:30‐3. ">Altamura 1985</a> only included 11. The majority randomised between 30 and 60 people. </p> </section> <section id="CD000307-sec-0085"> <h5 class="title">5. Interventions</h5> <p>Six of the included trials compared fluphenazine decanoate with placebo (<a href="./references#CD000307-bbs2-0015" title="DottiA , BersaniG , RubinoIA , ElliseoC . Double blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics [Studio in doppio cieco della flufenazina decanoato versus placebo nella terapia ambulatoriale di mantenimento di pazienti schizofrenici cronici]. Rivista di Psichiatria1979;14(5):374‐83. [MEDLINE: 75003702] ">Dotti 1979</a>; <a href="./references#CD000307-bbs2-0020" title="HirschSR . The interaction between depot‐phenothiazines and the social and clinical manifestations of behaviour in patients with stabilised chronic schizophrenia. In: VanPraagHM editor(s). On the Origin of Schizophrenic Psychoses. De Erven Bohn BV, 1975:209‐22. [MEDLINE: 76263054] ">Hirsch 1975</a>; <a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a>; <a href="./references#CD000307-bbs2-0063" title="ShenoyRS , SadlerSG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141‐5. ">Shenoy 1981</a>) and one study compared fluphenazine enanthate with placebo (<a href="./references#CD000307-bbs2-0068" title="VanPraagHM , BreetveldJ , VanMesdag‐ettyH , WesterhuisR , PenA , SchutT . A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria, Neurologia, Neurochirurgia1970;73:165‐75. ">Van Praag 1970</a>). Ten studies compared fluphenazine decanoate with enanthate (<a href="./references#CD000307-bbs2-0003" title="AltamuraAC , CurrySH , MontgomeryS , WilesDH . Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology1985;87:30‐3. ">Altamura 1985</a>; <a href="./references#CD000307-bbs2-0004" title="AsarnowRE , MarderSR , MintzJ , VanPuttenT , ZimmermanKE . Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information‐processing skills. Archives of General Psychiatry1988;45:822‐7. ">Asarnow 1988</a>; <a href="./references#CD000307-bbs2-0007" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1978;Feb‐Mar:148‐54. ">Chouinard 1978</a>; <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a>; <a href="./references#CD000307-bbs2-0014" title="DonlonPT , AxelradAD , TupinJP , ChienC . Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry1976;17(2):369‐76. ">Donlon 1976</a>; <a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>; <a href="./references#CD000307-bbs2-0032" title="KeskinerA , ItilT , HanH , HsuW , UlettG . EEG changes after fluphenazine enanthate and decanoate based on analog power spectra and digital computer period analysis. Psychopharmacologia1971;20(3):230‐41. [MEDLINE: 71275801] ">Keskiner 1971</a>; <a href="./references#CD000307-bbs2-0036" title="KurlandAA , RichardsonJH . A comparative study of two long acting phenothiazine preparations, fluphenazine enanthate and fluphenazine decanoate. Psychopharmacologia (Berl)1966;9:320‐7. ">Kurland 1966</a>; <a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a>; <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a>). Fourteen studies compared fluphenazine esters with oral antipsychotics. Thirty‐five trials compared fluphenazine decanoate or enanthate with other depot formulations. There were 10 dosage studies ‐ nine comparing fluphenazine decanoate and one comparing fluphenazine enanthate (<a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a>). Of the 73 included trials, 66 used fluphenazine decanoate as an intervention. </p> </section> <section id="CD000307-sec-0086"> <h5 class="title">6. Outcomes</h5> <section id="CD000307-sec-0087"> <h6 class="title">6.1 Outcome reporting</h6> <p>Many of the trials presented their findings in graphs or using P values alone. Graphical presentation made it impossible to acquire raw data for synthesis. Requests for raw data from authors have so far failed with the exception of <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a> and <a href="./references#CD000307-bbs2-0052" title="QuitkinF , RifkinA , KaneJ , Ramos‐LorenziJR , KleinDF . Long‐acting oral vs injectable antipsychotic drugs in schizophrenics. Archives of General Psychiatry1978;35:889‐92. ">Quitkin 1978</a>. It was also common to use P values as a measure of association between intervention and outcomes instead of showing the strength of the association. </p> </section> <section id="CD000307-sec-0088"> <h6 class="title">6.2 Missing outcomes</h6> <p>No study reported on hospital and service outcomes or commented on participants' overall satisfaction during or after the trial. Economic outcomes were not reviewed by any of the included studies. </p> </section> <section id="CD000307-sec-0089"> <h6 class="title">6.1 Outcome scales</h6> <p>Scales that provided usable data are listed below. We listed data that were not usable in the <a href="./references#CD000307-sec-0226" title="">Characteristics of included studies</a> under outcomes, 'unable to use'. </p> <section id="CD000307-sec-0090"> <p><b>6.1.1 Global functioning</b></p> <p>a) Clinical Global Impression ‐ CGI (<a href="./references#CD000307-bbs2-0307" title="GuyW . Clinincal Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is a three‐item rating instrument commonly used in schizophrenia studies. It enables clinicians to quantify the severity of illness and overall clinical improvement during therapy. A seven‐point scoring system is usually used with low scores indicating decreased severity and/or greater recovery. </p> <p>b) Global Assessment Scale ‐ GAS (<a href="./references#CD000307-bbs2-0303" title="EndicottJ , SpitzerRL , FleissJL , CohenJ . The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry1976;33(6):766‐71. ">Endicott 1976</a>)<br/> This is an observer‐rated scale for evaluating the overall functioning of an individual during a specified time period on a continuum from psychological or psychiatric sickness to health. Score ranges from zero to 100, where a higher score indicates better functioning. </p> </section> <section id="CD000307-sec-0091"> <p><b>6.1.2 Mental state</b></p> <p>a) Brief Psychiatric Rating Scale ‐ BPRS (<a href="./references#CD000307-bbs2-0329" title="OverallJE , GorhamDR . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>)<br/> The BPRS is an 18‐item scale measuring positive symptoms, general psychopathology and affective symptoms. The original scale has 16 items, but a revised 18‐item scale is commonly used. Scores can range from zero to 126. Each item is rated on a seven‐point scale, with high scores indicating more severe symptoms. </p> <p>b) Comprehensive Psychopathological Rating Scale ‐ CPRS (<a href="./references#CD000307-bbs2-0286" title="AsbergM , MontgomerySA , PerrisC , SchallingD , SedavllGA . A comprehensive psychopathological rating scale. Acta Psychiatria Scandinavca1978;Supp 271:5‐27. ">Asberg 1978</a>)<br/> The scale is designed to measure psychopathology over time via a clinical interview. It contains 67 items, including one global rating and one item documenting the reliability of the interview. The majority of the items (40) are based upon reported symptoms. Assumed reliability of the rating is scored as zero (very poor), one (fair), two (good) or three (very good). </p> <p>c) Krawiecka Scale (<a href="./references#CD000307-bbs2-0319" title="KrawieckaM , GoldbergD , VaughanM . A standardised psychiatric assessment scale for rating psychotic patients. Acta Psychiatria Scandinavica1977;55:299‐308. ">Krawiecka 1977</a>)<br/> This mental state scale encompasses both positive and negative symptoms of schizophrenia. It is used to evaluate the mental state and behaviour in chronic psychotic people with higher scores indicating greater severity. It is also known as the Manchester Scale. </p> <p>d) Scale for the Assessment of Negative Symptoms ‐ SANS (<a href="./references#CD000307-bbs2-0284" title="AndreasenNC . The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: Univ. of Iowa, 1983. ">Andreasen 1983</a>)<br/> This scale allows a global rating of the following negative symptoms: alogia (impoverished thinking), affective blunting, avolition‐apathy, anhedonia‐asociality, and attention impairment. Assessments are made on a six‐point scale from zero (not at all) to five (severe). Higher scores indicate more symptoms. </p> <p>e) Scale for the Assessment of Positive Symptoms ‐ SAPS (<a href="./references#CD000307-bbs2-0285" title="AndreasenNC . The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, Iowa: Univ. of Iowa, 1984. ">Andreasen 1984</a>)<br/> This six‐point scale gives a global rating of positive symptoms such as delusions, hallucinations and disordered thinking. Higher scores indicate more symptoms. </p> </section> <section id="CD000307-sec-0092"> <p><b>6.1.3 Behaviour</b></p> <p>a) Nurses Observational Scale of Inpatients Evaluation ‐ NOSIE (<a href="./references#CD000307-bbs2-0313" title="HonigfeldG , GillisRD , KlettCJ . NOSIE‐30: A treatment sensitive ward behavior scale. Psychological Reports1962;10:799‐812. ">Honigfeld 1962</a>).<br/> This is an 80‐item scale with items rated on a five‐point scale from zero (not present) to four (always present). Ratings are based on behaviour over the previous three days. The seven headings are social competence, social interest, personal neatness, co‐operation, irritability, manifest psychosis and psychotic depression. The total score ranges from zero to 320 with high scores indicating a poor outcome. </p> </section> <section id="CD000307-sec-0093"> <p><b>6.1.4 Adverse effects</b></p> <p>a) Abnormal Involuntary Movement Side Effects Scale ‐ AIMS (<a href="./references#CD000307-bbs2-0307" title="GuyW . Clinincal Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This is a 12‐item scale designed to record the occurrence of dyskinetic movements. Ten items of this scale have been used to assess tardive dyskinesia, a long‐term drug‐induced movement disorder. A five‐point scoring system (from zero ‐ none to four ‐ severe) has been used to rate each of the 10 items. Using this scale in short‐term treatment may be helpful in assessing some short‐term abnormal movement disorders. A low score indicates low levels of dyskinetic movements. </p> <p>b) Dosage Record and Treatment Emergent Symptoms Scale ‐ DOTES (<a href="./references#CD000307-bbs2-0307" title="GuyW . Clinincal Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This adverse effect tool seems less of a scale, where the degree and severity of a symptom is recorded, and more of a checklist. The DOTES seems to record the presence or absence of a list of adverse effects. </p> <p>c) Extrapyramidal Symptom Rating Scale ‐ ESRS (<a href="./references#CD000307-bbs2-0291" title="ChouinardG , Ross‐ChouinardA , AnnableL . Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science1980;7:233. ">Chouinard 1980</a>)<br/> This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. High scores indicate severe levels of movement disorder. </p> <p>d) Simpson and Angus Scale ‐ SAS (<a href="./references#CD000307-bbs2-0331" title="SimpsonGM , AngusJWS . A rating scale for extrapyramidal side effects. Acta Psychiatria Scandinavica1970;212:s11‐9. ">Simpson 1970b</a>)<br/> The SAS is a 10‐item scale, used to evaluate the presence and severity of drug‐induced parkinsonian symptomatology. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a zero to four scale, with a scoring system of zero to four for each item. This scale is referred to as the RSESE in <a href="./references#CD000307-bbs2-0027" title="JuH , CongZ , DengP . A control study on using pipothiazine palmitate to treat schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(1):24‐5. ">Ju 2000</a>. A low score indicates low levels of parkinsonism. </p> <p>e) UKU Side Effects Rating Scale ‐ UKU‐SERS (<a href="./references#CD000307-bbs2-0323" title="LingjaerdeO , AhlforsUG , BechP , DenckerSJ , ElgenK . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients. Acta PsychiatrIa Scandinavica Supplement1987;334:1‐100. ">Lingjaerde 1987</a>).<br/> The UKU rates four major topics: psychological adverse effects (10 items), neurological adverse effects (eight items), autonomic adverse effects (11 items) and other adverse effects (19 items). Each item is defined by means of a four‐point scale where zero means not present or doubtfully present. Scoring range zero to144. </p> <p>f) Treatment Emergent Symptom Scale ‐TESS (<a href="./references#CD000307-bbs2-0307" title="GuyW . Clinincal Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976. ">Guy 1976</a>)<br/> This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. High scores indicate worse symptoms. </p> <p>g) Symptom Checklist 90 ‐ SCL‐90 (<a href="./references#CD000307-bbs2-0297" title="DerogatisLR . SCL‐90‐R: Administration, procedures and scoring manual, for the revised version. Clinical Psychometrics Reasearch Unit , John Hopkins University, Baltimore1977. ">Derogatis 1977</a>)<br/> This is a self‐report scale of physical symptoms. </p> <p>h) Maryland Psychiatric Research Center Involuntary Movement Scale (<a href="./references#CD000307-bbs2-0290" title="CassadySL , ThackerGK , SummerfeltA , TammingaCA . The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Research1997;70(1):21‐37. ">Cassady 1997</a>)<br/> The MPRC rates the severity of tardive dyskinesia. It gives a global rating of dyskinesia in 11 body areas and two ratings during gait. It is rated on an eight‐point scale (zero to seven), with higher scores indicating worse symptoms. </p> </section> <section id="CD000307-sec-0094"> <p><b>6.1.5 Quality of life</b></p> <p>a) Quality of life scale – QLS (<a href="./references#CD000307-bbs2-0309" title="HeinrichDW , HanlonTE , CarpenterWT . The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin1984;10(3):388‐98. ">Heinrich 1984</a>)<br/> This 21‐item scale is based on a semi‐structured interview providing information on symptoms and functioning during the preceding four weeks. There are seven severity steps (zero to six; six being adequately functioning and zero being deficient). Four item categories have been identified by factor analysis i) interpersonal relationships (seven items), ii) instrumental role (four items), iii) intrapsychic function (seven items) and iv) common place objects and activities. Higher scores indicate better quality of life. </p> </section> </section> </section> </section> <section id="CD000307-sec-0095"> <h4 class="title">Excluded studies</h4> <p>We excluded 201 studies, mainly because they were not randomised controlled trials (RCTs), or controlled clinical trials (CCTs), because neither fluphenazine decanoate nor fluphenazine enanthate were included in the interventions or because trialists did not report any usable data. In the latter case, we contacted authors requesting raw data but we have, in most cases, received no reply. Other reasons for exclusion were that the two drugs were not analysed (<a href="./references#CD000307-bbs2-0011" title="CrawfordR , ForrestA . Controlled trial of depot fluphenazine in out‐patient schizophrenics. British Journal of Psychiatry1974;124:385‐91. ">Crawford 1974</a>; <a href="./references#CD000307-bbs2-0272" title="WistedtB , PalmstiernaT . Depressive symptoms in chronic schizophrenic patients after withdrawal of long‐acting neuroleptics. Journal of Clinical Psychiatry1983;44:369‐71. ">Wistedt 1983a</a>) or clinical outcomes were not measured (<a href="./references#CD000307-bbs2-0194" title="LandmarkJ , MerskeyH , CernovskyZZ . Fluphenazine treatment of DSM‐III‐R Male Schizophrenic Patients Among the Xhosa. Canadian Journal of Psychiatry1994;39:219‐22. ">Landmark 1994</a>; <a href="./references#CD000307-bbs2-0201" title="LeffJP , HirschSR , GaindR , RohdePD , StevensBC . Life events and maintenance therapy in schizophrenic therapy. British Journal of Psychiatry1973;123:659‐69. ">Leff 1973</a>; <a href="./references#CD000307-bbs2-0209" title="MarderSR , VanPuttenT , AravagiriM , HawesEM , HubbardJW , McKayG , et al. Fluphenazine plasma levels and clinical response. Psychopharmacology Bulletin1990;26(2):256‐9. ">Marder 1990a</a>; <a href="./references#CD000307-bbs2-0210" title="MarderSR , MidhaKK , VanPuttenT , AravagiriM , HawesEM , HubbardJW , et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. British Journal of Psychiatry1991;158:658‐65. ">Marder 1991a</a>; <a href="./references#CD000307-bbs2-0252" title="StevensBC . Role of fluphenazine decanaote in lessening the burden of chronic schizophrenics on the community. Psychological Medicine1973;3:141‐58. ">Stevens 1973</a>). </p> <section id="CD000307-sec-0096"> <h5 class="title">Awaiting assessment</h5> <p>Six studies await assessment. <a href="./references#CD000307-bbs2-0276" title="delGiudiceJ , OkunR , ClarkWG . Recidivism with long acting fluphenazine. VII meeting of the International College of Neuropsychopharmacology. 1970. [MEDLINE: 21196608] ">del Giudice 1970</a>; <a href="./references#CD000307-bbs2-0277" title="JueFY , WangCZ , YueXC , FangYR , XueHD , ChenSX . Flupentixol vs fluphenazine in schizophrenia patients: a randomized controlled trial. New Drugs and Clinical Remedies1996;15(1):19‐22. ">Jue 1996</a>; <a href="./references#CD000307-bbs2-0278" title="KabesJ , FilipV , SikoraJ . A multiclinical study of the effectiveness of meclopin in maintenance therapy of schizophrenic patients ‐ A DOUBLE‐blind crossover comparative study with flufenazine decanoate. Farmakoterapeuticke Zpravy1984;30(2):159‐81. ">Kabes 1984</a>; <a href="./references#CD000307-bbs2-0279" title="RavanicDB , Djukic‐DejanovicSM , StojiljkovicM , JankovicS , PaunovicVR , BankovicD . Antipsychotic efficacy of clozapine vs fluphenazine in positive and negative schizophrenia syndrome. Journal of Neural Transmission1996;103:XLVI. [MEDLINE: 20445745] ">Ravanic 1996</a> are reports for which we have citations but no papers. These are currently being sought. Two papers await translation (<a href="./references#CD000307-bbs2-0275" title="AngstJ , FreiM , ScharfetterC . The depot neuroleptic agent fluspirilene. Pharmakopsychiatrie und Neuropsychopharmakologie1973;6:13‐28. ">Angst 1973</a>; <a href="./references#CD000307-bbs2-0280" title="UshakovIV , KravchenkoNE , KopeikoGI , KaluginaLI , MirzoianMG . Clinical and economic approach to evaluation of the effectiveness of moditen‐depot and haloperidol decanoate in the maintenance therapy of attack‐like schizophrenia [Klinicheskii ekonomicheskii podkhod k otsenke sravnitel'noi effektivnosti moditena‐depo i galoperidola dekanoata v podderzhi‐ vaiushchei terapii u bol’nykh pristupoobraznoi shizofreniei.]. Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova1990;90(7):99‐104. [MEDLINE: 91075905] ">Ushakov 1990a</a>). </p> </section> <section id="CD000307-sec-0097"> <h5 class="title">Ongoing studies</h5> <p>We have not identified any ongoing studies.</p> </section> </section> </section> <section id="CD000307-sec-0098"> <h3 class="title">Risk of bias in included studies</h3> <p>See also 'Risk of bias' tables in <a href="./references#CD000307-sec-0226" title="">Characteristics of included studies</a>, and <a href="#CD000307-fig-0003">Figure 3</a> and <a href="#CD000307-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD000307-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000307-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000307-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000307-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Since the last version of this review was published, the methods for assessing the risk of bias of studies has changed. All studies were re‐assessed for risk of bias in the current version of this review. The risk of bias has not been fully assessed for two studies as they are not reported in English and we were not able to translate them (<a href="./references#CD000307-bbs2-0030" title="KanenoS , OhkumaT , YamashitaI , MoriA , YagiG , KudoY , et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Rinsho Hyoka (Clinical Evaluation)1991;19(1):15‐45. [MEDLINE: 70166858] ">Kaneno 1991</a>; <a href="./references#CD000307-bbs2-0054" title="RossiA , DiMicheleVD , VolonteMV , CasacchiaM . Therapeutic evaluation of bromperidol decanoate in schizophrenia ‐ a double‐blind comparison vs. Fluphenazine decanoate [Efficacia terapeutica e tollerabilita del Bromperidolo decanoato VS Flufenazina decanoato nel Disturbo Schizofrenico]. Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali1990;114(6):1379‐86. ">Rossi 1990</a>), although <a href="./references#CD000307-bbs2-0030" title="KanenoS , OhkumaT , YamashitaI , MoriA , YagiG , KudoY , et al. A double blind comparative study on the efficacy and safety of fluphenazine decanoate (SQ10, 733) and oral haloperidol in the treatment of schizophrenic patients. Rinsho Hyoka (Clinical Evaluation)1991;19(1):15‐45. [MEDLINE: 70166858] ">Kaneno 1991</a> had a section in English and the risk of bias has been completed based on this. </p> <section id="CD000307-sec-0099"> <h4 class="title">Allocation</h4> <p>All included studies were reported as randomised, but only five described the method of randomisation: <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a> used a coin‐throwing method, <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a> a randomisation code, <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a> a pre‐arranged prescribing list, and <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a> a randomisation list. <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> described the method of randomisation as the next available study number in the numerical sequence. However only <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a> was rated as low risk, <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> was rated to be a high risk and the other studies were all rated as unclear risk of bias for sequence generation. </p> <p>Three other studies did not report method of randomisation but did describe allocation concealment (<a href="./references#CD000307-bbs2-0031" title="KellyHB , FreemanHL , BanningB , SchiffAA . Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. International Pharmacopsychiatry1977;12:54‐64. ">Kelly 1977</a>; <a href="./references#CD000307-bbs2-0036" title="KurlandAA , RichardsonJH . A comparative study of two long acting phenothiazine preparations, fluphenazine enanthate and fluphenazine decanoate. Psychopharmacologia (Berl)1966;9:320‐7. ">Kurland 1966</a>; <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a>). In these three trials the allocation codes were known only to the hospital pharamcists or nurses involved in the trial, and were rated as low risk of bias; the remaining studies were rated as unclear risk of bias. </p> </section> <section id="CD000307-sec-0100"> <h4 class="title">Blinding</h4> <p>Most studies reported using double‐blind methodology, although the technique used was not described in the majority of these studies. Seven studies were rated low risk of bias for blinding of participants and personnel, and stated blindness was achieved through use of identical injections of medication (<a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a>; <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a>; <a href="./references#CD000307-bbs2-0011" title="CrawfordR , ForrestA . Controlled trial of depot fluphenazine in out‐patient schizophrenics. British Journal of Psychiatry1974;124:385‐91. ">Crawford 1974</a>; <a href="./references#CD000307-bbs2-0014" title="DonlonPT , AxelradAD , TupinJP , ChienC . Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry1976;17(2):369‐76. ">Donlon 1976</a>; <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a>; <a href="./references#CD000307-bbs2-0049" title="McLarenS , CooksonJ , SilverstoneJ . A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic. Annual Meeting of the British Association for Psychopharmacology; 1990 July 15, Cambridge, England. 1990. McLarenS , CooksonJC , SilverstoneT . Postive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromoperidol and fluphenazine decanoates. International Clinical Psychopharmacology1992;7(2):67‐72. ">McLaren 1992</a>; <a href="./references#CD000307-bbs2-0068" title="VanPraagHM , BreetveldJ , VanMesdag‐ettyH , WesterhuisR , PenA , SchutT . A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria, Neurologia, Neurochirurgia1970;73:165‐75. ">Van Praag 1970</a>). </p> <p>Only 14 studies described outcome assessors as being blinded to treatment and were rated low risk of bias (<a href="./references#CD000307-bbs2-0003" title="AltamuraAC , CurrySH , MontgomeryS , WilesDH . Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology1985;87:30‐3. ">Altamura 1985</a>; <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a>; <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>; <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a>; <a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a>; <a href="./references#CD000307-bbs2-0028" title="KaneJ , QuitkinF , RifkinA , KleinDF . Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. American Journal of Psychiatry1978;135:1539‐42. ">Kane 1978</a>; <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a>; <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a>; <a href="./references#CD000307-bbs2-0055" title="RussellN , LandmarkJ , MerskeyH , TurpinT . A double‐blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Canadian Journal of Psychiatry1982;27:593‐6. ">Russell 1982</a>; <a href="./references#CD000307-bbs2-0068" title="VanPraagHM , BreetveldJ , VanMesdag‐ettyH , WesterhuisR , PenA , SchutT . A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatria, Neurologia, Neurochirurgia1970;73:165‐75. ">Van Praag 1970</a>; <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a>; <a href="./references#CD000307-bbs2-0071" title="WistedtB , RantaJ . Comparative double‐blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandinavica1983;67:378‐88. ">Wistedt 1983</a>). <a href="./references#CD000307-bbs2-0042" title="MagnusRV . A comparative study of fluspirilene and fluphenazine decanoate in schizophrenic patients. Journal of Pharmacotherapy1979;2(3):109‐14. MagnusRV . Fluspirilene and fluphenazine decanoate for schizophrenic patients. Controlled study [Fluspirilen und Fluphenazin‐Dekanoat bei schizophrenen Patienten. Vergleichende Studie]. Munchener Medizinische Wochenschriftenschrift1980;122:1758‐60. ">Magnus 1979</a> and <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a> were open label trials and <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> described using a 'partially‐blinded' method where only outcome assessors were blinded. The remaining studies were of unclear risk of bias as no information on blinding of outcome assessors was provided. </p> </section> <section id="CD000307-sec-0101"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐nine studies were rated as low risk of bias for incomplete outcome data and 25 studies had an unclear risk of bias. Seventeen studies were rated as high risk of bias, for two of these it was due to more than 50% of losses to follow‐up (<a href="./references#CD000307-bbs2-0024" title="JainRC , AnanthJV , LehmannHE , BanTA . A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients. Current Therapeutic Research1975;18(4):585‐9. ">Jain 1975</a>; <a href="./references#CD000307-bbs2-0034" title="KisslingW , MollerHJ , WalterK , WittmanB , KrueggerR , TrenkD . Double‐blind comparison of haloperidol and fluphenazine decanoate effectiveness, side effects, dosage and serum levels during a six months treatment for relapse prevention. Pharmacopsychiatry1985;18:240‐5. ">Kissling 1985</a>), and only data for the outcome "Leaving the study early" was used for these studies. </p> </section> <section id="CD000307-sec-0102"> <h4 class="title">Selective reporting</h4> <p>Only 12 studies were of low risk of bias with regard to selective reporting, and five were unclear. The remaining studies were of high risk of bias, mainly due to poor data reporting. Continuous data were particularly problematic as many studies presented findings without standard deviations or any other measure of variance, in graphs, in percentiles or by inexact P values. Furthermore, many pre‐planned outcomes were not reported at all. </p> </section> <section id="CD000307-sec-0103"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD000307-bbs2-0048" title="McKaneJP , RobinsonADT , WilesDH , McCreadieRG , StirlingGS . Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in‐patients. British Journal of Psychiatry1987;151:333‐6. ">McKane 1987</a> and <a href="./references#CD000307-bbs2-0049" title="McLarenS , CooksonJ , SilverstoneJ . A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic. Annual Meeting of the British Association for Psychopharmacology; 1990 July 15, Cambridge, England. 1990. McLarenS , CooksonJC , SilverstoneT . Postive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromoperidol and fluphenazine decanoates. International Clinical Psychopharmacology1992;7(2):67‐72. ">McLaren 1992</a> were subject to other biases as they were funded by the pharmaceutical industry. Eighteen studies were rated as low risk of bias for other potential sources of bias, and the remaining had an unclear risk of bias. </p> </section> </section> <section id="CD000307-sec-0104"> <h3 class="title" id="CD000307-sec-0104">Effects of interventions</h3> <p>See: <a href="./full#CD000307-tbl-0001"><b>Summary of findings for the main comparison</b> FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</a>; <a href="./full#CD000307-tbl-0002"><b>Summary of findings 2</b> FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</a>; <a href="./full#CD000307-tbl-0003"><b>Summary of findings 3</b> FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</a> </p> <p>We calculated risk ratios (RR) for dichotomous data and estimated mean differences (MD) for continuous data, with their respective 95% confidence intervals (CIs) throughout. </p> <section id="CD000307-sec-0105"> <h4 class="title">COMPARISON 1: FLUPHENAZINE DECANOATE versus PLACEBO</h4> <section id="CD000307-sec-0106"> <h5 class="title">1.1 Death</h5> <p>The only study reporting mortality was <a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a> where two deaths occurred in the treatment group (fluphenazine decanoate) compared to none in the placebo group (n = 54, RR 5.00, CI 0.30 to 99.51). Nevertheless, the result was not statistically significant (<a href="./references#CD000307-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD000307-sec-0107"> <h5 class="title">1.2 Global state</h5> <p>Heterogeneous data from three studies (<a href="./references#CD000307-bbs2-0020" title="HirschSR . The interaction between depot‐phenothiazines and the social and clinical manifestations of behaviour in patients with stabilised chronic schizophrenia. In: VanPraagHM editor(s). On the Origin of Schizophrenic Psychoses. De Erven Bohn BV, 1975:209‐22. [MEDLINE: 76263054] ">Hirsch 1975</a>; <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a>; <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a>) found relapse rates to be equivocal over six months to one year for the fluphenazine decanoate group compared with people receiving placebo (n = 196, 3 RCTs, RR 0.62, CI 0.24 to 1.60). <a href="./references#CD000307-bbs2-0063" title="ShenoyRS , SadlerSG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141‐5. ">Shenoy 1981</a> reported no relapses in the short term at six weeks. Relapse rates for longer‐term studies (<a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>) at two years significantly favoured fluphenazine decanoate (n = 54, RR 0.35, CI 0.19 to 0.64) compared to placebo (<a href="./references#CD000307-fig-0006" title="">Analysis 1.2</a>). </p> <p>Furthermore, one short‐term study of six weeks found no significant difference between treatment group when global state was measured on the Global Assessment Scale (GAS) (<a href="./references#CD000307-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD000307-sec-0108"> <h5 class="title">1.3 Leaving the study early</h5> <p>Four trials in which 216 people had been randomised to fluphenazine decanoate or placebo had, in total, 21% attrition (<a href="./references#CD000307-fig-0008" title="">Analysis 1.4</a>). No significant difference was found in people leaving the study early between groups (RR 1.30, CI 0,77 to 2.19). <a href="./references#CD000307-bbs2-0063" title="ShenoyRS , SadlerSG , GoldbergSC , HamerRM , RossB . Effects of a six‐week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Journal of Clinical Psychopharmacology1981;1:141‐5. ">Shenoy 1981</a> reported short‐term data at six weeks and also found no significant difference between treatment groups. <a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a> reported longer‐term data at two years for leaving the study early that significantly favoured depot fluphenazine compared to placebo (n = 54, RR 0.47, CI 0.23 to 0.96). </p> </section> <section id="CD000307-sec-0109"> <h5 class="title">1.4 Mental state</h5> <p>Only one trial (<a href="./references#CD000307-bbs2-0015" title="DottiA , BersaniG , RubinoIA , ElliseoC . Double blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics [Studio in doppio cieco della flufenazina decanoato versus placebo nella terapia ambulatoriale di mantenimento di pazienti schizofrenici cronici]. Rivista di Psichiatria1979;14(5):374‐83. [MEDLINE: 75003702] ">Dotti 1979</a>) reported general mental state on the Brief Psychiatric Rating Scale (BPRS), the results were equivocal (<a href="./references#CD000307-fig-0009" title="">Analysis 1.5</a>). The single study by <a href="./references#CD000307-bbs2-0050" title="OdejideOA , AderounmuAF . Double‐blind placebo substitution: Withdrawal of fluphenazine decanoate in schizophrenic patients. Psychopharmacology1982;43(5):195‐6. ">Odejide 1982</a> reporting on depression showed equivocal results between fluphenazine decanoate and placebo (<a href="./references#CD000307-fig-0010" title="">Analysis 1.6</a>). </p> </section> <section id="CD000307-sec-0110"> <h5 class="title">1.5 Adverse effects</h5> <p>Limited data were available. <a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a> reported equivocal data for incidence of tardive dyskinesia (<a href="./references#CD000307-fig-0011" title="">Analysis 1.7</a>). <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a> reported on toxicity (no further details reported), which was significantly higher in the depot fluphenazine group (n = 45 RR, 7.65, CI 1.04 to 56.26; <a href="./references#CD000307-fig-0012" title="">Analysis 1.8</a>). </p> </section> </section> <section id="CD000307-sec-0111"> <h4 class="title">COMPARISON 2: FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS</h4> <section id="CD000307-sec-0112"> <h5 class="title">2.1 Death</h5> <p>There were no reports of death in any of the studies comparing depot fluphenazine versus other oral neuroleptics. </p> </section> <section id="CD000307-sec-0113"> <h5 class="title">2.2 Global state</h5> <p>Using the negative outcome, 'no clinically important global change' <a href="./references#CD000307-bbs2-0001" title="AdamsonL , CurreySH , BridgesPK , FirestoneAF , LavinNI , LewisDM , et al. Fluphenazine decanoate trial in chronic inpatient schizophrenics failing to absorb oral chlorpromazine. Diseases of the Nervous System1973;34(4):181‐91. ">Adamson 1973</a> and <a href="./references#CD000307-bbs2-0012" title="CurrySH , AdamsonL . Double‐blind trial of fluphenazine decanoate. Lancet1972;2(776):543‐4. ">Curry 1972</a> produced results favouring fluphenazine decanoate at 0 to 5 weeks (n = 74, 2 RCTs, RR 0.61 CI 0.46 to 0.81; <a href="./references#CD000307-fig-0013" title="">Analysis 2.1</a>). <a href="./references#CD000307-bbs2-0067" title="SongY . A double‐blind control study on the effect of pipotiazine palmitate and fluphenazine decanoate in the treatment of schizophrenia [data not available]. Chinese Journal of Neurology and Psychiatry1993;26(3):137‐40. ">Song 1993</a> reported on outcomes at 6 months to one year, with equivocal findings (n = 102, RR 0.85, CI 0.56 to 1.27). Using the CGI scale, <a href="./references#CD000307-bbs2-0064" title="ShuL . Double‐blind study of domestic penfluridol and fluphenazine decanoate. Chung Hua Shen Ching Ching Shen Ko Tsa Chih (Chinese Journal of Neurology and Psychiatry)1983;16(3):141‐5. [MEDLINE: 84083784] ">Shu 1983</a> also reported equivocal findings (n = 34, MD at 6 weeks ‐0.10 CI ‐2.79 to 2.59; <a href="./references#CD000307-fig-0015" title="">Analysis 2.3</a>). There was no significant difference between those taking fluphenazine decanoate and people on oral neuroleptics for relapse at 6 months to one year (n = 419, 6 RCTs, RR 1.46, CI 0.75 to 2.83); relapse data recorded at more than one year were also not significant (n = 216, 3 RCTs, RR 1.25 0.81 to 1.95; <a href="./references#CD000307-fig-0014" title="">Analysis 2.2</a>). </p> </section> <section id="CD000307-sec-0114"> <h5 class="title">2.3 Leaving the study early</h5> <p>Nine trials reported no significant difference between the number of people who left the study early over six months to one year in either the fluphenazine decanoate group or the oral antipsychotic group (n = 887, RR 0.96, CI 0.73 to 1.25; <a href="./references#CD000307-fig-0016" title="">Analysis 2.4</a>). Studies by <a href="./references#CD000307-bbs2-0012" title="CurrySH , AdamsonL . Double‐blind trial of fluphenazine decanoate. Lancet1972;2(776):543‐4. ">Curry 1972</a> (at 28 days), <a href="./references#CD000307-bbs2-0064" title="ShuL . Double‐blind study of domestic penfluridol and fluphenazine decanoate. Chung Hua Shen Ching Ching Shen Ko Tsa Chih (Chinese Journal of Neurology and Psychiatry)1983;16(3):141‐5. [MEDLINE: 84083784] ">Shu 1983</a> (at six weeks) and <a href="./references#CD000307-bbs2-0016" title="FallonI , WattDC , ShepherdM . The social outcome of patients in a trial of long‐term continuation therapy in schizophrenia: pimozide vs fluphenazine. Psychological Medicine1978;8:265‐74. FalloonI , WattD . A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine1978;8:59‐70. ShepherdM . Medical‐social evaluation of the long term pharmacotherapy of schizophrenia. Progress Neuro‐Psychopharmacology1979;3:383‐9. ">Falloon 1978</a> and <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a> (at more than one year) were also equivocal. </p> </section> <section id="CD000307-sec-0115"> <h5 class="title">2.4 Behaviour</h5> <p><a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a> found no difference in Nurses Observational Scale of Inpatients Evaluation (NOSIE) scale scores between groups (n = 120, MD ‐0.56, CI ‐6.92 to 5.80; <a href="./references#CD000307-fig-0017" title="">Analysis 2.5</a>). <a href="./references#CD000307-bbs2-0005" title="BarnesTRE , MilavicG , CursonDA , PlattSD . Use of the social behaviour assessment schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Social Psychiatry1983;18:193‐9. ">Barnes 1983</a> reported a significant difference for change in disturbed behaviour (n = 36); these data are skewed (<a href="./references#CD000307-fig-0018" title="">Analysis 2.6</a>). </p> </section> <section id="CD000307-sec-0116"> <h5 class="title">2.5 Mental state</h5> <p>Only <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>, reported on mental state (BPRS endpoint scores) and found no significant difference between groups (n = 120, MD ‐0.75, CI ‐5.75 to 4.25; <a href="./references#CD000307-fig-0019" title="">Analysis 2.7</a>). <a href="./references#CD000307-bbs2-0059" title="SchoolerNR , LevineJ , SevereJB . Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen. Psychopharmacology Bulletin1979;15(2):44‐7. ">Schooler 1979</a> and <a href="./references#CD000307-bbs2-0016" title="FallonI , WattDC , ShepherdM . The social outcome of patients in a trial of long‐term continuation therapy in schizophrenia: pimozide vs fluphenazine. Psychological Medicine1978;8:265‐74. FalloonI , WattD . A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine1978;8:59‐70. ShepherdM . Medical‐social evaluation of the long term pharmacotherapy of schizophrenia. Progress Neuro‐Psychopharmacology1979;3:383‐9. ">Falloon 1978</a> reporting on depression found no significant difference between those receiving fluphenazine decanoate and oral neuroleptics (n = 214, RR six months to one year 0.89, CI 0.60 to 1.32; n = 44, RR more than one year 1.53,CI 0.91 to 2.57; <a href="./references#CD000307-fig-0020" title="">Analysis 2.8</a>). </p> </section> <section id="CD000307-sec-0117"> <h5 class="title">2.6 Adverse effects</h5> <p>Three studies, <a href="./references#CD000307-bbs2-0046" title="McCreadieRG , DingwallJM , WilesDH , HeykantsJJP . Intermittant pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1980;137:510‐7. ">McCreadie 1980</a>, <a href="./references#CD000307-bbs2-0047" title="McCreadieR , MackieM , MorrisonD , KiddJ . Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1982;140:280‐6. ">McCreadie 1982</a> and <a href="./references#CD000307-bbs2-0060" title="GelenbergAJ , DollarJC , SchoolerNR , MieskeM , SevereJ , MandelMR . Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Amercian Journal of Psychiatry1979;136(2):217‐9. LevineJ , SchoolerNR , SevereJ , EscobarJ , GelebergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients ater one year of continuous medication: A controlled study. Advanced Biochemical Psychopharmacology1980;24:483‐93. MandelMR , SevereJB , SchoolerNR , GelenbergAJ , MieskeM . Development and prediction of postpsychotic depression in neuroleptic‐treated schizophrenics. Archives of General Psychiatry1982;39:197‐203. SchoolerNR , LevineJ , NIMH‐PRB Collaborative Fluphenazine Study Group. The initiation of long‐term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine. Pharmakopsychiatria1976;9:159‐69. SchoolerNR , LevineJ , SevereJB , BrauzerB , DiMascioA , KlermanGL , et al. Prevention of relapse in schizophrenia ‐ An evaluation of fluphenazine decanoate. Archives of General Psychiatry1980;37:16‐24. ">Schooler 1980</a>, report homogenous data for general movement disorders (six months to one year), which significantly favoured fluphenazine decanoate compared to oral neuroleptics (n = 259, RR 0.47, CI 0.24 to 0.91; <a href="./references#CD000307-fig-0021" title="">Analysis 2.9</a>). The single longer‐term study by <a href="./references#CD000307-bbs2-0016" title="FallonI , WattDC , ShepherdM . The social outcome of patients in a trial of long‐term continuation therapy in schizophrenia: pimozide vs fluphenazine. Psychological Medicine1978;8:265‐74. FalloonI , WattD . A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine1978;8:59‐70. ShepherdM . Medical‐social evaluation of the long term pharmacotherapy of schizophrenia. Progress Neuro‐Psychopharmacology1979;3:383‐9. ">Falloon 1978</a> found no significant difference for incidence of movement disorders (n = 44, RR 0.40, CI 0.12 to 1.28). <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a> reported on akathisia at one year. Akathisia was significantly lower in the oral fluphenazine group (n = 51, RR 20.54 CI 1.25 to 337.94; <a href="./references#CD000307-fig-0022" title="">Analysis 2.10</a>). Trials reported limited data for the outcome 'needing anticholinergic drugs' and all findings were equivocal (<a href="./references#CD000307-fig-0023" title="">Analysis 2.11</a>). <a href="./references#CD000307-bbs2-0047" title="McCreadieR , MackieM , MorrisonD , KiddJ . Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1982;140:280‐6. ">McCreadie 1982</a> found tardive dyskinesia to be significantly less common for those allocated fluphenazine decanoate compared with people on pimozide (n = 28, RR medium term 0.62, CI 0.41 to 0.93; <a href="./references#CD000307-fig-0024" title="">Analysis 2.12</a>). The other study that reported on tardive dyskinesia was <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>. Trialists did not find any difference between fluphenazine decanoate and oral neuroleptic (n = 120, RR at 18 months 0.16, CI 0.01 to 2.99). <a href="./references#CD000307-bbs2-0064" title="ShuL . Double‐blind study of domestic penfluridol and fluphenazine decanoate. Chung Hua Shen Ching Ching Shen Ko Tsa Chih (Chinese Journal of Neurology and Psychiatry)1983;16(3):141‐5. [MEDLINE: 84083784] ">Shu 1983</a>, using the Simpson and Angus Scale (SAS) reported no significant difference at six weeks between fluphenazine decanoate and penfluridol (n = 32, MD 1.30, CI 0.01 to 2.59; <a href="./references#CD000307-fig-0026" title="">Analysis 2.14</a>). <a href="./references#CD000307-bbs2-0001" title="AdamsonL , CurreySH , BridgesPK , FirestoneAF , LavinNI , LewisDM , et al. Fluphenazine decanoate trial in chronic inpatient schizophrenics failing to absorb oral chlorpromazine. Diseases of the Nervous System1973;34(4):181‐91. ">Adamson 1973</a> (immediate), <a href="./references#CD000307-bbs2-0047" title="McCreadieR , MackieM , MorrisonD , KiddJ . Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia. British Journal of Psychiatry1982;140:280‐6. ">McCreadie 1982</a> and <a href="./references#CD000307-bbs2-0060" title="GelenbergAJ , DollarJC , SchoolerNR , MieskeM , SevereJ , MandelMR . Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Amercian Journal of Psychiatry1979;136(2):217‐9. LevineJ , SchoolerNR , SevereJ , EscobarJ , GelebergA , MandelM , et al. Discontinuation of oral and depot fluphenazine in schizophrenic patients ater one year of continuous medication: A controlled study. Advanced Biochemical Psychopharmacology1980;24:483‐93. MandelMR , SevereJB , SchoolerNR , GelenbergAJ , MieskeM . Development and prediction of postpsychotic depression in neuroleptic‐treated schizophrenics. Archives of General Psychiatry1982;39:197‐203. SchoolerNR , LevineJ , NIMH‐PRB Collaborative Fluphenazine Study Group. The initiation of long‐term pharmacotherapy in schizophrenia: dosage and side effect comparison between oral and depot fluphenazine. Pharmakopsychiatria1976;9:159‐69. SchoolerNR , LevineJ , SevereJB , BrauzerB , DiMascioA , KlermanGL , et al. Prevention of relapse in schizophrenia ‐ An evaluation of fluphenazine decanoate. Archives of General Psychiatry1980;37:16‐24. ">Schooler 1980</a> (medium term) reported general adverse effects. Outcomes are equivocal (<a href="./references#CD000307-fig-0029" title="">Analysis 2.17</a>). <a href="./references#CD000307-bbs2-0016" title="FallonI , WattDC , ShepherdM . The social outcome of patients in a trial of long‐term continuation therapy in schizophrenia: pimozide vs fluphenazine. Psychological Medicine1978;8:265‐74. FalloonI , WattD . A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychological Medicine1978;8:59‐70. ShepherdM . Medical‐social evaluation of the long term pharmacotherapy of schizophrenia. Progress Neuro‐Psychopharmacology1979;3:383‐9. ">Falloon 1978</a> was the only longer‐term study to report on tremor, with equivocal results for depot fluphenazine and pimozide (n = 44, RR 0.80, CI 0.26 to 2.45; <a href="./references#CD000307-fig-0025" title="">Analysis 2.13</a>). <a href="./references#CD000307-bbs2-0058" title="SchoolerNR , LevineJ , NIMH‐PRB Collaborative Fluphenazine Study Group. The initiation of long‐term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. Pharmakopsychiatria1976;9(4):159‐69. ">Schooler 1976</a> reports equivocal data for the adverse effect of blurred vision (<a href="./references#CD000307-fig-0027" title="">Analysis 2.15</a>). <a href="./references#CD000307-bbs2-0053" title="RifkinA , QuitkinF , KaneJ , KleinDF . Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics II. Rating scale data. Psychopharmacology Bulletin1977;13(2):40‐50. RifkinA , QuitkinF , KaneJ , KleinDF , RossD . The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics. Biological Psychiatry1979;14(3):499‐508. RifkinA , QuitkinF , KleinD . Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics ‐ Rating scale data. Archives of General Psychiatry1977;34:15‐9. RifkinA , QuitkinF , RabinerC , KleinDF . Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics ‐ Relapse years after one year. Archives of General Psychiatry1977;34:43‐7. ">Rifkin 1977</a> also reported on toxicity (no further details), which was more frequent for the depot fluphenazine group (n = 51, RR 4.87, CI 1.14 to 20.72; <a href="./references#CD000307-fig-0028" title="">Analysis 2.16</a>). </p> </section> </section> <section id="CD000307-sec-0118"> <h4 class="title">COMPARISON 3: FLUPHENAZINE DECANOATE versus OTHER DEPOT NEUROLEPTICS</h4> <section id="CD000307-sec-0119"> <h5 class="title">3.1 Death</h5> <p><a href="./references#CD000307-bbs2-0048" title="McKaneJP , RobinsonADT , WilesDH , McCreadieRG , StirlingGS . Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in‐patients. British Journal of Psychiatry1987;151:333‐6. ">McKane 1987</a> reported one death occurring in the treatment group (fluphenazine decanoate) compared to none in the haloperidol decanoate group (n = 38, RR 3.0, CI 0.13 to 69.31; <a href="./references#CD000307-fig-0031" title="">Analysis 3.1</a>). Nevertheless, the result was not statistically significant. </p> </section> <section id="CD000307-sec-0120"> <h5 class="title">3.2 Global state</h5> <p>Eleven studies reported the outcome of 'relapse' at six months to one year. We found no statistically significant difference between the fluphenazine decanoate group and the other depot groups (n = 581, RR 0.82, CI 0.56 to 1.18). Longer studies (more than one year) also found no difference between interventions (n = 252, RR 1.22, CI 0.77 to 1.92). <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a> did report relapse data at 20 weeks but, again, results were equivocal (<a href="./references#CD000307-fig-0033" title="">Analysis 3.3</a>). Outcomes for 'no clinically important global change' at six months to one year reported by <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>, <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> and <a href="./references#CD000307-bbs2-0056" title="SchlosbergA , ShadmiM . A comparative controlled study of two long‐acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642‐54. ">Schlosberg 1978</a> were not significant for the fluphenazine decanoate and other depot neuroleptic groups (n = 187, RR 1.04, CI 0.96 to 1.12; <a href="./references#CD000307-fig-0032" title="">Analysis 3.2</a>); <a href="./references#CD000307-bbs2-0027" title="JuH , CongZ , DengP . A control study on using pipothiazine palmitate to treat schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(1):24‐5. ">Ju 2000</a> also reported short‐term data and also found no significant difference. <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> supported this result by reporting no significant differences in the number of people who became severely ill in the comparison of fluphenazine decanoate with other depot drugs (n = 60, RR 1.07, CI 0.94 to 1.23; <a href="./references#CD000307-fig-0034" title="">Analysis 3.4</a>). </p> <p><a href="./references#CD000307-bbs2-0009" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ChouinardG , AnnableL , CampbellW , BoisvertD , BradwejnJ . A double‐blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacology Bulletin1984;20:108‐9. ">Chouinard 1984</a> and <a href="./references#CD000307-bbs2-0056" title="SchlosbergA , ShadmiM . A comparative controlled study of two long‐acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642‐54. ">Schlosberg 1978</a> report continuous data at six months to one year on clinical global impression. There is no clear advantage between fluphenazine decanoate and other depot neuroleptics (n = 90, MD ‐0.10, CI ‐0.41 to 0.21; <a href="./references#CD000307-fig-0037" title="">Analysis 3.7</a>). These findings were confirmed by <a href="./references#CD000307-bbs2-0009" title="ChouinardG , AnnableL , CampbellW . A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Journal of Clinical Psychopharmacology1989;9(4):247‐53. ChouinardG , AnnableL , CampbellW , BoisvertD , BradwejnJ . A double‐blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacology Bulletin1984;20:108‐9. ">Chouinard 1984</a> and <a href="./references#CD000307-bbs2-0010" title="CooksonJC , KennedyNM , GribbonD . Weight gain and prolactin levels in patients on long‐term antipsychotic medication: a double‐blind comparative trial of haloperidol decanoate and fluphenazine decanaote. International Clinical Psychopharmacology1986;Suppl 1:41‐51. ">Cookson 1986</a> who reported no significant difference in needing additional antipsychotics at six months to one year between the depot groups (n = 91, RR 0.53, CI 0.14 to 1.96; <a href="./references#CD000307-fig-0035" title="">Analysis 3.5</a>). <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a> also reported the outcome of 'not improved' (n = 50, RR at four months RR 2.50, CI 0.53 to 11.70) and <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a>, at seven months (n = 60, RR 0.75, CI 0.18 to 3.07) (<a href="./references#CD000307-fig-0038" title="">Analysis 3.8</a>). Finally, <a href="./references#CD000307-bbs2-0072" title="WistedtB . A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients. International Clinical Psychopharmacology1986;1(Suppl 1):15‐23. WistedtB , PerssonT , HelbomE . A clinical double‐blind comparison between haloperidol decanoate and fluphenazine decanoate. Current Therapeutic Research1984;35(5):804‐14. ">Wistedt 1984</a> reported non‐significant data for clinical global impression at zero to five weeks. These data are skewed so are not displayed graphically (<a href="./references#CD000307-fig-0036" title="">Analysis 3.6</a>). </p> </section> <section id="CD000307-sec-0121"> <h5 class="title">3.3 Leaving the study early</h5> <p>Fifteen included trials found no significant difference in the number of people who left the study early in either the fluphenazine decanoate group or the other depot group (n = 775, RR medium term 1.13, CI 0.89 to 1.44). Studies found no differences across any time period from the immediate to those lasting longer than one year (<a href="./references#CD000307-fig-0039" title="">Analysis 3.9</a>). </p> </section> <section id="CD000307-sec-0122"> <h5 class="title">3.4 Behaviour</h5> <p><a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a> supported this outcome by reporting no difference in NOSIE‐30 scores between the groups (n = 118, MD ‐ ‐5.21 ‐10.85 to 0.43; <a href="./references#CD000307-fig-0040" title="">Analysis 3.10</a>). </p> </section> <section id="CD000307-sec-0123"> <h5 class="title">3.5 Mental state</h5> <p>We found short‐ and medium‐term studies assessing mental state (BPRS endpoint scores) to significantly favour 'other depot neuroleptics' for the short term (n = 203, 2 RCTs MD 1.11, CI 0.86 to 1.36) and medium term (n = 162, 3 RCTs, MD 1.20, CI 1.10 to 1.30) (<a href="./references#CD000307-fig-0041" title="">Analysis 3.11</a>). Longer‐term studies (<a href="./references#CD000307-bbs2-0048" title="McKaneJP , RobinsonADT , WilesDH , McCreadieRG , StirlingGS . Haloperidol decanoate versus fluphenazine decanoate as maintenance therapy in chronic schizophrenic in‐patients. British Journal of Psychiatry1987;151:333‐6. ">McKane 1987</a>, <a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>) did not show any differences for mental state in either intervention (n = 141, MD 0.85 CI ‐2.32 to 4.03; Analysis 3.11). Dichotomised medium‐term BPRS data reported by <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a> found no significant difference between depot fluphenazine and pipothiazine palmitate (<a href="./references#CD000307-fig-0042" title="">Analysis 3.12</a>). The only study reporting on the outcome of depression was <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a> who found no significant difference between fluphenazine decanoate and pipothiazine palmitate (n = 67, RR medium term 1.02, CI 0.81 to 1.28; <a href="./references#CD000307-fig-0043" title="">Analysis 3.13</a>). <a href="./references#CD000307-bbs2-0027" title="JuH , CongZ , DengP . A control study on using pipothiazine palmitate to treat schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(1):24‐5. ">Ju 2000</a> reported data for positive and negative symptoms on the Scale for the Assessment of Positive Symptom(SAPS) and SANS, respectively, from six weeks to five months, but these data are skewed so are not displayed graphically (<a href="./references#CD000307-fig-0044" title="">Analysis 3.14</a>). </p> </section> <section id="CD000307-sec-0124"> <h5 class="title">3.6 Adverse effects</h5> <p>The occurrence of dyskinetic movements in general was the same across short‐, medium‐ and longer‐term studies (<a href="./references#CD000307-fig-0045" title="">Analysis 3.15</a>). <a href="./references#CD000307-bbs2-0017" title="FengL . Double blind controlled trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenia. Chinese Journal of Nervous and Mental Disorders1990;16(5):299. ">Feng 1990</a> reporting on a small, short‐term study found no significant difference between fluphenazine decanoate and haloperidol decanoate (n = 30 RR 2.00, CI 0.43 to 9.32). <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>, <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> and <a href="./references#CD000307-bbs2-0056" title="SchlosbergA , ShadmiM . A comparative controlled study of two long‐acting phenothiazines: Pipothiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1978;23(5):642‐54. ">Schlosberg 1978</a> (comparing fluphenazine decanoate with pipothiazide palmitate) and <a href="./references#CD000307-bbs2-0049" title="McLarenS , CooksonJ , SilverstoneJ . A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic. Annual Meeting of the British Association for Psychopharmacology; 1990 July 15, Cambridge, England. 1990. McLarenS , CooksonJC , SilverstoneT . Postive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromoperidol and fluphenazine decanoates. International Clinical Psychopharmacology1992;7(2):67‐72. ">McLaren 1992</a> (comparing with bromperidol decanoate) found no significant difference in the occurrence of dyskinestic movements (n = 234, RR at six months to one year 1.08, CI 0.86 to 1.34). Longer‐term studies also found no significant difference with movement disorders between fluphenazine decanoate and other depot neuroleptics. For the outcome of 'needing anticholinergic medication', eight studies, when synthesised, found in favour of other depots by one year (n = 448, RR 1.24 0.93 to 1.64 ). However, these data were heterogeneous and using the random‐effects model (as per protocol), the result was not statistically significant (<a href="./references#CD000307-fig-0046" title="">Analysis 3.16</a>). For the same outcome, three longer‐term studies were equivocal but significantly favoured the 'other depot neuroleptics' group when analysed with a fixed‐effect model (n = 220, RR 1.28, CI 1.08 to 1.51). Outcomes such as dry mouth, tardive dyskinesia and parkinsonism were not significantly different between depot fluphenazine and other depot neuroleptics (<a href="./references#CD000307-fig-0052" title="">Analysis 3.22</a>; <a href="./references#CD000307-fig-0048" title="">Analysis 3.18</a>; <a href="./references#CD000307-fig-0047" title="">Analysis 3.17</a>, respectively). Tremor (short term, 2 RCTs and medium term, 3 RCTs) was not more common for people given the depot flupenthixol (<a href="./references#CD000307-fig-0049" title="">Analysis 3.19</a>). <a href="./references#CD000307-bbs2-0027" title="JuH , CongZ , DengP . A control study on using pipothiazine palmitate to treat schizophrenic patients. Journal of Clinical Psychological Medicine2000;10(1):24‐5. ">Ju 2000</a> reported data for movement disorders from six weeks to five months on the TESS and RSESE, but these data are skewed so are not displayed graphically (<a href="./references#CD000307-fig-0050" title="">Analysis 3.20</a>). When reporting blurred vision, the results of one medium term trial were not significant, but one longer‐term study, <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a>, did report significant results (P = 0.04) favouring flupenthixol decanoate (n = 64, RR 17.88, CI 1.08 to 294.82; <a href="./references#CD000307-fig-0051" title="">Analysis 3.21</a>). General adverse effects (short‐term data) were reported by <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a> and <a href="./references#CD000307-bbs2-0025" title="JavedMA , ChaudhryMR . Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Pakistan Journal of Clinical Psychiatry1991;1(2):69‐74. ">Javed 1991</a> and favoured other depot neuroleptics (n = 88, RR 1.36, CI 1.07 to 1.74). However, medium‐term data (n = 249, six months to one year) were equivocal (<a href="./references#CD000307-fig-0053" title="">Analysis 3.23</a>). </p> </section> </section> <section id="CD000307-sec-0125"> <h4 class="title">COMPARISON 4: FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES (HIGH DOSE versus STANDARD DOSE)</h4> <section id="CD000307-sec-0126"> <h5 class="title">4.1 Global state</h5> <p><a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a> and <a href="./references#CD000307-bbs2-0035" title="KreismanD , BlumenthalR , BorensteinM , WoernerM , KaneJ , RifkinA , et al. Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low‐dose neuroleptics: the family's view. Psychiatry1988;51(1):3‐13. [MEDLINE: 88218101] ">Kreisman 1988</a> reported no significant difference in relapse scores (medium term) between either depot group (n = 182, RR 2.11, CI 0.30 to 14.91; <a href="./references#CD000307-fig-0055" title="">Analysis 4.1</a>). Also, <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a> reported no significant difference in needing additional antipsychotics (six months to one year) between fluphenazine decanoate (high dose) group and the standard dosage groups (n = 50, 1 RCTs, RR 1.67, CI 0.45 to 6.24; <a href="./references#CD000307-fig-0056" title="">Analysis 4.2</a>). Outcomes for global improvement 'not improved' were reported by <a href="./references#CD000307-bbs2-0037" title="LehmannE , QuadbeckH , TegelerJ , FararuniM , HeinrichK . Drug‐response differences of high and standard dosage of fluphenazine‐decanoate in relation to schizophrenic symptoms. Pharmakopsychiatrie und Neuropsychopharmakologie1980;13(3):117‐29. ">Lehmann 1980</a> (nurse and psychiatrist rated) at six months to one year (<a href="./references#CD000307-fig-0057" title="">Analysis 4.3</a>). Results for nurse rated outcomes significantly favoured the standard dosage group (n = 40, 1 RCT, RR 1.58, CI 1.09 to 2.30). However, results for psychiatrist rated were not significant for either dosage intervention at six months (n = 40, 1 RCT, RR 1.15, CI 0.77 to 1.74). </p> </section> <section id="CD000307-sec-0127"> <h5 class="title">4.2 Leaving the study early</h5> <p><a href="./references#CD000307-bbs2-0037" title="LehmannE , QuadbeckH , TegelerJ , FararuniM , HeinrichK . Drug‐response differences of high and standard dosage of fluphenazine‐decanoate in relation to schizophrenic symptoms. Pharmakopsychiatrie und Neuropsychopharmakologie1980;13(3):117‐29. ">Lehmann 1980</a> and <a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a> reported no difference in the number leaving the study (six months to one year) for either intervention (n = 90, 2 RCTs, RR 0.60, CI 0.15 to 2.36; <a href="./references#CD000307-fig-0058" title="">Analysis 4.4</a>). </p> </section> <section id="CD000307-sec-0128"> <h5 class="title">4.3 Mental state</h5> <p><a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a> further reported no difference in BPRS endpoint score (n = 50, 1 RCT, MD ‐0.03, CI ‐5.79 to 5.73) for either the high or standard dosage group (<a href="./references#CD000307-fig-0059" title="">Analysis 4.5</a>). </p> </section> <section id="CD000307-sec-0129"> <h5 class="title">4.4 Adverse effects</h5> <p><a href="./references#CD000307-bbs2-0045" title="McClellandH , FarquharsonRG , LeyburnP , FurnessJA , SchiffAA . Very high dose fluphenazine decanoate. Archives of General Psychiatry1976;33:1435‐9. ">McClelland 1976</a> reported no difference between the groups for those needing anticholinergic medication (n = 50, RR 1.67, CI 0.45 to 6.24) at six months to one year, suggesting the incidence of adverse effects is comparable between the groups, as the use of anticholinergic drugs is considered to be a direct measure of the severity of adverse effects due to medication (<a href="./references#CD000307-fig-0060" title="">Analysis 4.6</a>). </p> </section> </section> <section id="CD000307-sec-0130"> <h4 class="title">COMPARISON 5: FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ (LOW DOSE versus STANDARD DOSE) </h4> <section id="CD000307-sec-0131"> <h5 class="title">5.1 Global state</h5> <p>Relapse data, assessed over six months to one year were equivocal. Longer‐term studies (more than one year) reported by <a href="./references#CD000307-bbs2-0004" title="AsarnowRE , MarderSR , MintzJ , VanPuttenT , ZimmermanKE . Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information‐processing skills. Archives of General Psychiatry1988;45:822‐7. ">Asarnow 1988</a>, <a href="./references#CD000307-bbs2-0022" title="HogartyGE , McEvoyJP , MunetzM , DiBarryAL , BartoneP , CatherR , et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry1988;45:797‐805. ">Hogarty 1988</a> and <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a> were also equivocal (<a href="./references#CD000307-fig-0061" title="">Analysis 5.1</a>). </p> </section> <section id="CD000307-sec-0132"> <h5 class="title">5.2 Leaving the study early</h5> <p><a href="./references#CD000307-bbs2-0004" title="AsarnowRE , MarderSR , MintzJ , VanPuttenT , ZimmermanKE . Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information‐processing skills. Archives of General Psychiatry1988;45:822‐7. ">Asarnow 1988</a>, <a href="./references#CD000307-bbs2-0022" title="HogartyGE , McEvoyJP , MunetzM , DiBarryAL , BartoneP , CatherR , et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry1988;45:797‐805. ">Hogarty 1988</a>, and <a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a> reported no difference in the number of people who left the study early in each dosage group after more than one year of medication (n = 172, RR 0.67, CI 0.33 to 1.36; <a href="./references#CD000307-fig-0062" title="">Analysis 5.2</a>). </p> </section> <section id="CD000307-sec-0133"> <h5 class="title">5.3 Mental state</h5> <p>The data obtained for mental state (e.g. BPRS score etc.) were skewed and therefore could not be included in the analyses. </p> </section> <section id="CD000307-sec-0134"> <h5 class="title">5.4 Adverse effects</h5> <p><a href="./references#CD000307-bbs2-0044" title="MarderSR , VanPuttenT , MintzJ , LebellM , McKenzieJ , MayPRA . Low and conventional dose maintenance therapy with fluphenazine decanoate. Archives of General Psychiatry1987;44:518‐21. MarderSR , VanPuttenT , MintzJ , McKenzieJ , LebellM , FalticoG , et al. Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry1984;41:1025‐9. ">Marder 1987</a> reported that there was no significant difference in the number of people requiring additional anticholinergic drugs at six months to one year (n = 50, RR 2.55, CI 0.72 to 9.05). <a href="./references#CD000307-bbs2-0029" title="KaneJM , RifkinA , WoernerM , ReardonG . Low‐dose neuroleptics in outpatient schizophrenics. Psychopharmacology Bulletin1982;18(1):20‐1. KaneJM , RifkinA , WoernerM , ReardonG , SarantakosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry1983;40:893‐6. ">Kane 1983</a> supported this finding by reporting that the number of people with tardive dyskinesia (n = 126, RR 0.52, CI 0.10 to 2.72) at six months to one year, was not significantly different between the groups receiving low doses of fluphenazine decanoate and standard dosage fluphenazine. <a href="./references#CD000307-bbs2-0029" title="KaneJM , RifkinA , WoernerM , ReardonG . Low‐dose neuroleptics in outpatient schizophrenics. Psychopharmacology Bulletin1982;18(1):20‐1. KaneJM , RifkinA , WoernerM , ReardonG , SarantakosS , SchiebelD , et al. Low‐dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry1983;40:893‐6. ">Kane 1983</a>, however, did report a statistically significant (P = 0.03) difference at endpoint analysis with the Simpson Dyskinesia Scale (n = 126), which favoured low‐dose fluphenazine decanoate, although data were skewed and therefore not graphically reported (<a href="./references#CD000307-fig-0063" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD000307-sec-0135"> <h4 class="title">COMPARISON 6: FLUPHENAZINE ENANTHATE versus PLACEBO</h4> <section id="CD000307-sec-0136"> <h5 class="title">6.1 Adverse effects ‐ at eight weeks</h5> <p>Only <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a> reported for this comparison. This small trial reported no significant difference in the number of people needing anticholinergic drugs in the fluphenazine enanthate and placebo groups (n = 25, RR 9.69, CI 0.58 to 163.02; <a href="./references#CD000307-fig-0065" title="">Analysis 6.1</a>). </p> </section> </section> <section id="CD000307-sec-0137"> <h4 class="title">COMPARISON 7. FLUPHENAZINE ENANTHATE versus ORAL NEUROLEPTICS</h4> <section id="CD000307-sec-0138"> <h5 class="title">7.1 Global state</h5> <p><a href="./references#CD000307-bbs2-0006" title="ChienCP , ColeJO . Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study. American Journal of Psychiatry1973;130(1):13‐7. ">Chien 1973</a> reported no significant difference in global change (immediate term, zero to five weeks) between fluphenazine enanthate and chlorpromazine (n = 31, RR 0.67, CI 0.27 to 1.66; <a href="./references#CD000307-fig-0066" title="">Analysis 7.1</a>). </p> </section> <section id="CD000307-sec-0139"> <h5 class="title">7.2 Adverse effects</h5> <p>Reports of adverse effects, again from the same study and for the immediate term were all not significantly different (n = 31, RR movement disorders 2.34, CI 0.53 to 10.30; RR general adverse effects 2.81, CI 0.94 to 8.45; RR parkinsonism 6.56, CI 0.91 to 47.21; <a href="./references#CD000307-fig-0067" title="">Analysis 7.2</a>). </p> </section> </section> <section id="CD000307-sec-0140"> <h4 class="title">COMPARISON 8: FLUPHENAZINE ENANTHATE versus OTHER DEPOT NEUROLEPTICS</h4> <section id="CD000307-sec-0141"> <h5 class="title">8.1 Global state</h5> <p><a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a> and <a href="./references#CD000307-bbs2-0007" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1978;Feb‐Mar:148‐54. ">Chouinard 1978</a> reported no significant difference in needing additional antipsychotics (at six months to one year) for fluphenazine enanthate compared with other depot groups (n = 65, RR 0.50, CI 0.24 to 1.05; <a href="./references#CD000307-fig-0068" title="">Analysis 8.1</a>). Both <a href="./references#CD000307-bbs2-0043" title="MalmU , PerrisC , RappW , WedrenG . A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes. Acta Psychiatrica Scandinavica Supplementum1974;249:94‐116. ">Malm 1974</a>, at six weeks to five months (n = 57, RR 2.38, CI 0.66 to 8.61) and <a href="./references#CD000307-bbs2-0007" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1978;Feb‐Mar:148‐54. ">Chouinard 1978</a>, at six months to one year (n = 32, RR 0.33, CI 0.04 to 2.87) reported no statistically significant differences in relapse rates between the fluphenazine enanthate group and the other depot (pipothiazine palmitate) groups (<a href="./references#CD000307-fig-0069" title="">Analysis 8.2</a>). </p> </section> <section id="CD000307-sec-0142"> <h5 class="title">8.2 Leaving the study early</h5> <p>Only <a href="./references#CD000307-bbs2-0024" title="JainRC , AnanthJV , LehmannHE , BanTA . A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients. Current Therapeutic Research1975;18(4):585‐9. ">Jain 1975</a> provided data for numbers leaving the study early (zero to five weeks). These data significantly favoured fluphenazine enanthate compared with the other depot neuroleptics ‐ pipothiazine palmitate (n = 30, RR 0.09, CI 0.01 to 0.62). However, this outcome should be interpreted with caution given the limited number of participants. The number of people who left the study early by six weeks to five months, in the single study by <a href="./references#CD000307-bbs2-0043" title="MalmU , PerrisC , RappW , WedrenG . A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes. Acta Psychiatrica Scandinavica Supplementum1974;249:94‐116. ">Malm 1974</a> using fluspirilene as a control, was not significant (n = 57, RR 2.38, CI 0.66 to 8.61). Similarly, <a href="./references#CD000307-bbs2-0007" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1978;Feb‐Mar:148‐54. ">Chouinard 1978</a> found no difference between the fluphenazine enanthate group and the other depot neuroleptic group ‐ pipothiazine palmitate at six months to one year (n = 32, RR 0.33, CI 0.04 to 2.87) (<a href="./references#CD000307-fig-0070" title="">Analysis 8.3</a>). </p> </section> <section id="CD000307-sec-0143"> <h5 class="title">8.3 Mental state</h5> <p><a href="./references#CD000307-bbs2-0066" title="SinghAN , SaxenaB . A comparative study of prolonged action (depot) neuroleptics: pipotiazine palmitate versus fluphenazine enanthate in chronic schizophrenic patients. Current Therapeutic Research1979;25(1):121‐32. ">Singh 1979</a> reported general BPRS scores and found a significant difference between the two groups favouring the other depot group (n = 30, MD 0.40, CI 0.34 to 0.46; <a href="./references#CD000307-fig-0071" title="">Analysis 8.4</a>). Specific scores on, for example, depression found no difference between the two groups (<a href="./references#CD000307-bbs2-0066" title="SinghAN , SaxenaB . A comparative study of prolonged action (depot) neuroleptics: pipotiazine palmitate versus fluphenazine enanthate in chronic schizophrenic patients. Current Therapeutic Research1979;25(1):121‐32. ">Singh 1979</a>, n = 30, RR 7.00, CI 0.39 to 124.83; <a href="./references#CD000307-fig-0072" title="">Analysis 8.5</a>). </p> </section> <section id="CD000307-sec-0144"> <h5 class="title">8.4 Adverse effects</h5> <p>Findings were equivocal for outcomes of 'movement disorders' (medium term: n = 63, 2 RCTs, RR 1.52, CI 0.75 to 3.07; <a href="./references#CD000307-fig-0073" title="">Analysis 8.6</a>), tardive dyskinesia (medium term: n = 32, 1 RCT, RR 0.89, CI 0.46 to 1.71; <a href="./references#CD000307-fig-0075" title="">Analysis 8.8</a>), tremor (medium term: n = 95, 3 RCTs, RR 1.24, CI 0.82 to 1.87; <a href="./references#CD000307-fig-0076" title="">Analysis 8.9</a>), blurred vision (medium term: n = 30, 1 RCT, RR 3.00, CI 0.13 to 68.26; <a href="./references#CD000307-fig-0077" title="">Analysis 8.10</a>) and dry mouth (medium term: n = 62, 2 RCTs, RR 0.80, CI 0.36 to 1.76; <a href="./references#CD000307-fig-0078" title="">Analysis 8.11</a>). <a href="./references#CD000307-bbs2-0043" title="MalmU , PerrisC , RappW , WedrenG . A multicenter controlled trial of fluspirilene and fluphenazine enanthate in chronic schizophrenic syndromes. Acta Psychiatrica Scandinavica Supplementum1974;249:94‐116. ">Malm 1974</a> reported that those receiving fluspirilene required significantly less anticholinergic drugs at six weeks to five months than the fluphenazine enanthate group (n = 57, RR 2.86, CI 1.16 to 7.06). The numbers of people needing additional anticholinergic drugs at six months to one year were found (<a href="./references#CD000307-bbs2-0002" title="AlbertJM , ElieR , CooperSF . Long term double‐blind evaluation of pipotiazine palmitate and fluphenazine decanoate. Current Therapeutic Research1980;27(6):897‐907. ">Albert 1980</a>; <a href="./references#CD000307-bbs2-0007" title="ChouinardG , AnnableL , KropskyM . A double‐blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Psychopharmacology1978;Feb‐Mar:148‐54. ">Chouinard 1978</a>) to be equivocal (n = 65, RR 1.02, CI 0.76 to 1.35) for the fluphenazine enanthate and other depot neuroleptic groups (<a href="./references#CD000307-fig-0074" title="">Analysis 8.7</a>). </p> </section> </section> <section id="CD000307-sec-0145"> <h4 class="title">COMPARISON 9: FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES (LOW DOSE versus INTERMEDIATE/HIGH DOSE) </h4> <section id="CD000307-sec-0146"> <h5 class="title">9.1 Global state</h5> <p>A single study by <a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a> reported the global outcome of relapse at six weeks to five months (<a href="./references#CD000307-fig-0079" title="">Analysis 9.1</a>). Trialists found statistically significant differences favouring the high‐dosage fluphenazine enanthate group compared with low‐dosage fluphenazine enanthate (n = 104, RR 9.35, CI 2.28 to 38.29). For every fourth person administered a low dose of fluphenazine decanoate, one would relapse. However, this result must be treated with caution as only one study is involved. </p> </section> <section id="CD000307-sec-0147"> <h5 class="title">9.2 Leaving the study early</h5> <p><a href="./references#CD000307-bbs2-0019" title="GoldsteinMJ , RodnickEH , EvansJR , MayPRA , SteinbergMR . Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry1978;35:1169‐77. ">Goldstein 1978</a> found no significant difference in the number of people who left the study early (six weeks to five months) whilst receiving either high or low dosages of fluphenazine enanthate (n = 104, RR 3.12, CI 0.66 to 14.74; <a href="./references#CD000307-fig-0080" title="">Analysis 9.2</a>). </p> </section> </section> <section id="CD000307-sec-0148"> <h4 class="title">COMPARISON 10: FLUPHENAZINE DECANOATE versus FLUPHENAZINE ENANTHATE</h4> <section id="CD000307-sec-0149"> <h5 class="title">10.1 Global state</h5> <p><a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a> reported data for 'needing additional antipsychotic treatment' at zero to five weeks (<a href="./references#CD000307-fig-0081" title="">Analysis 10.1</a>). This trial found a significant difference between the fluphenazines (decanoate and enanthate) (n = 33, RR 0.39, CI 0.18 to 0.86). <a href="./references#CD000307-bbs2-0008" title="ChouinardG , AnnableL , Ross‐ChouinardA . Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: Extrapyramidal symptoms and therapeutic effect. American Journal of Psychiatry1982;139(3):312‐18. ">Chouinard 1982</a> was the only study to report the numbers of people requiring additional antipsychotic treatment at six months to one year and found no significant difference. </p> <p>The number of people who relapsed whilst receiving medication at zero to five weeks was not significant for the two studies available (n = 44, 2 RCTs, RR 0.66, CI 0.18 to 2.43). <a href="./references#CD000307-bbs2-0014" title="DonlonPT , AxelradAD , TupinJP , ChienC . Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry1976;17(2):369‐76. ">Donlon 1976</a> reported no significant difference in relapse rates at six weeks to five months between the fluphenazine decanoate group and the fluphenazine enanthate group (n = 30, RR 2.29, CI 0.70 to 7.48). <a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a>, reporting on relapse over the medium term (six months to one year) found no significant difference (n = 49, RR 2.43, CI 0.71 to 8.32) (<a href="./references#CD000307-fig-0082" title="">Analysis 10.2</a>). </p> </section> <section id="CD000307-sec-0150"> <h5 class="title">10.2 Leaving the study early</h5> <p>The number of people leaving the study early (<a href="./references#CD000307-fig-0083" title="">Analysis 10.3</a>) at zero to five weeks was not significantly different between the fluphenazine decanoate and enanthate groups (n = 44, 2 RCTs, RR 0.66, CI 0.18 to 2.43). Short term outcomes (6 weeks to 5 months) were also not significantly different between the fluphenazine ester groups (n = 42, 2 RCTs, RR 2.29 CI 0.70 to 7.48). Medium‐term data (six months to one year) were consistent with the results of the two shorter study periods, finding no difference in the number of people leaving the study early for the two fluphenazine ester groups (n = 49, 1 RCT, RR 2.43, CI 0.71 to 8.32). </p> </section> <section id="CD000307-sec-0151"> <h5 class="title">10.3 Mental state</h5> <p>Only one study by <a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a> reported on mental state, using BPRS endpoint scores at one year. They found no significant difference between the fluphenazine esters (n = 39, MD 0.00, CI ‐3.93 to 3.93; (<a href="./references#CD000307-fig-0084" title="">Analysis 10.4</a>). </p> </section> <section id="CD000307-sec-0152"> <h5 class="title">10.4 Adverse effects</h5> <p>The number of people in these studies reporting movement disorders for immediate (zero to five weeks) or short term (six weeks to five months) was not significantly different between the fluphenazine esters (<a href="./references#CD000307-fig-0085" title="">Analysis 10.5</a>). Reports of adverse effects (zero to five weeks), parkinsonism (six weeks to five months) and akathisia (zero to five weeks) were equivocal for fluphenazine decanoate and enanthate groups (<a href="./references#CD000307-fig-0089" title="">Analysis 10.9</a>; <a href="./references#CD000307-fig-0087" title="">Analysis 10.7</a>; <a href="./references#CD000307-fig-0088" title="">Analysis 10.8</a>, respectively). </p> <p>The number of people needing anticholinergic drugs at zero to five weeks was found by <a href="./references#CD000307-bbs2-0069" title="VanPraagHM , DolsLCW . Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry1973;130(7):801‐4. ">Van Praag 1973</a> to be significantly lower for the fluphenazine decanoate group (n = 33, RR 0.29, CI 0.12 to 0.70). For longer‐term studies (six weeks to five months and six months to one year) there were no significant differences in the number of people needing anticholinergic drugs (<a href="./references#CD000307-fig-0086" title="">Analysis 10.6</a>). </p> </section> </section> <section id="CD000307-sec-0153"> <h4 class="title">COMPARISON 11: FLUPHENAZINE DECANOATE EVERY TWO WEEKS versus EVERY SIX WEEKS</h4> <p>We found only one relevant trial (<a href="./references#CD000307-bbs2-0033" title="KhazaeiH , HabibiF , PourafkariN . The effect of fluphenazine decanoate every 2 weeks versus 6 weeks in the treatment of schizophrenia and schizoaffective disorders. Iranian Journal of Psychiatry and Clinical Psychology2003;8(4):11‐5. KhazaieH , ShakeriJ . Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate. Archives of Iranian Medicine2005;8(2):109‐14. ">Khazaie 2005</a>) that compared the use of fluphenazine decanoate every two weeks with every six weeks. </p> <section id="CD000307-sec-0154"> <h5 class="title">11.1 Global state</h5> <p>There was no significant difference between fluphenazine decanoate every two weeks and every six weeks in the number of participants relapsing (n = 37, RR 0.89, CI 0.55 to 1.44; <a href="./references#CD000307-fig-0090" title="">Analysis 11.1</a>). </p> </section> <section id="CD000307-sec-0155"> <h5 class="title">11.2 Leaving the study early</h5> <p>The number of participants leaving the study early also did not differ significantly between fluphenazine decanoate every two weeks and every six weeks (n = 37, RR 1.17, CI 0.46 to 2.98; <a href="./references#CD000307-fig-0091" title="">Analysis 11.2</a>). </p> </section> <section id="CD000307-sec-0156"> <h5 class="title">11.3 Mental state</h5> <p>Total BPRS scores were not significantly different between fluphenazine decanoate every two weeks and every six weeks (n = 37, MD 2.72, CI ‐1.16 to 6.60, <a href="./references#CD000307-fig-0092" title="">Analysis 11.3</a>), nor was the BPRS sub‐scale for thought disorder (n = 37, MD ‐0.39, CI ‐1.51 to 0.73; <a href="./references#CD000307-fig-0092" title="">Analysis 11.3</a>). </p> </section> <section id="CD000307-sec-0157"> <h5 class="title">11.4 Adverse effects</h5> <p>There was no significant difference between fluphenazine decanoate every two weeks and every six weeks in parkinsonian symptoms (n = 37, MD 1.30, CI ‐0.03 to 2.63) and dyskinesia (n = 37, MD 2.40, CI ‐1.77 to 6.57) measured on the Maryland Psychiatric Research Center Involuntary Movement Scale (MPRC) scale (<a href="./references#CD000307-fig-0093" title="">Analysis 11.4</a>). </p> </section> <section id="CD000307-sec-0158"> <h5 class="title">11.5 Quality of life</h5> <p>We did not find any difference between fluphenazine decanoate every two weeks and every six weeks in the quality of life of participants (n = 37, MD 1.42, CI ‐9.68 to 12.52, <a href="./references#CD000307-fig-0094" title="">Analysis 11.5</a>). </p> </section> </section> <section id="CD000307-sec-0159"> <h4 class="title">12. Subgroup analyses</h4> <p>The only primary outcome with enough studies (at least six) to warrant subgroup analysis was relapse from Comparison 2 and Comparison 3. However, studies either included chronic patients, a mix of chronic and acute, or did not report the stage of the illness, therefore, it was not possible to undertake any subgroup analyses. </p> </section> <section id="CD000307-sec-0160"> <h4 class="title">13. Sensitivity analysis</h4> <p>The only primary outcome with enough studies (at least six) to warrant sensitivity analysis was relapse from Comparison 2 and Comparison 3. </p> <section id="CD000307-sec-0161"> <h5 class="title">13.1 Implication of randomisation</h5> <p>All trials were described as randomised in the review.</p> </section> <section id="CD000307-sec-0162"> <h5 class="title">13.2 Assumptions for lost binary data</h5> <p>We did not make any assumptions about lost binary data.</p> </section> <section id="CD000307-sec-0163"> <h5 class="title">13.3 Risk of bias</h5> <p>For relapse at medium term in Comparison 2 (<a href="./references#CD000307-fig-0033" title="">Analysis 3.3</a>), only <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> had a high risk of bias for randomisation. The results remained non‐significant with the removal of this trial. For this outcome, all trials had a high risk of bias for selective reporting except, again, for <a href="./references#CD000307-bbs2-0038" title="LeongOK , WongKE , TayWK , GillRC . A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Medical Journal1989;30:536‐40. ">Leong 1989</a> and results were unchanged. </p> <p>For relapse at medium term in Comparison 3 (<a href="./references#CD000307-fig-0014" title="">Analysis 2.2</a>), all studies had unclear risk of bias for randomisation and all had a high or unclear risk of bias for selective reporting. </p> </section> <section id="CD000307-sec-0164"> <h5 class="title">13.4 Imputed values</h5> <p>We did not have any cluster randomised trials and did not impute any data.</p> </section> <section id="CD000307-sec-0165"> <h5 class="title">13.5 Dose</h5> <p>The mean daily dose of fluphenazine decanoate at endpoint ranged from 0.3 to 300 mg and for fluphenazine enanthate ranged from 2.35 to 387.5 mg. Two studies, <a href="./references#CD000307-bbs2-0010" title="CooksonJC , KennedyNM , GribbonD . Weight gain and prolactin levels in patients on long‐term antipsychotic medication: a double‐blind comparative trial of haloperidol decanoate and fluphenazine decanaote. International Clinical Psychopharmacology1986;Suppl 1:41‐51. ">Cookson 1986</a> and <a href="./references#CD000307-bbs2-0012" title="CurrySH , AdamsonL . Double‐blind trial of fluphenazine decanoate. Lancet1972;2(776):543‐4. ">Curry 1972</a>, did not specify the average dose. The way data were reported did not permit any more sensitivity analyses than those which have already been presented. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000307-sec-0166" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000307-sec-0166"></div> <section id="CD000307-sec-0167"> <h3 class="title" id="CD000307-sec-0167">Summary of main results</h3> <p>Seventy‐three trials including 4870 participants were included in the review. The summary below reflects the outcomes chosen for <a href="./full#CD000307-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD000307-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD000307-tbl-0003">summary of findings Table 3</a>, and are considered the main findings of this review. Overall, the quality of the evidence was rated as low to very low. </p> <section id="CD000307-sec-0168"> <h4 class="title">1. Fluphenazine decanoate versus placebo</h4> <section id="CD000307-sec-0169"> <h5 class="title">1.1 Death</h5> <p>Only one, small study (<a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>) reported on death and no significant differences were observed. </p> </section> <section id="CD000307-sec-0170"> <h5 class="title">1.2 Global state</h5> <section id="CD000307-sec-0171"> <h6 class="title">1.2.1 Clinically significant change in global state</h6> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0172"> <h6 class="title">1.2.2 Relapse</h6> <p>Very low quality evidence from three studies showed that medium‐term relapse rates were not significantly lower in the fluphenazine decanoate group (43%) compared with placebo (67%). Only longer‐term data from one small trial (<a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>) significantly reduced relapse. </p> </section> </section> <section id="CD000307-sec-0173"> <h5 class="title">1.3 Hospital admission</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0174"> <h5 class="title">1.4 Leaving the study early</h5> <p>The numbers of people leaving the study early in the fluphenazine decanoate (24%) and placebo (19%) groups were very similar, however, the quality of the evidence was very low. This figure could be higher in clinical practice because rigorous adherence to protocols in these randomised studies may decrease attrition, although the opposite could also be true. Although adherence to protocol improves internal validity, it can potentially decrease the external validity and applicability of results. The single two‐year study significantly favoured fluphenazine decanoate compared with placebo (<a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>). </p> </section> <section id="CD000307-sec-0175"> <h5 class="title">1.5 Mental state</h5> <p>One very small study (<a href="./references#CD000307-bbs2-0015" title="DottiA , BersaniG , RubinoIA , ElliseoC . Double blind trial of fluphenazine decanoate against placebo in ambulant maintenance treatment of chronic schizophrenics [Studio in doppio cieco della flufenazina decanoato versus placebo nella terapia ambulatoriale di mantenimento di pazienti schizofrenici cronici]. Rivista di Psichiatria1979;14(5):374‐83. [MEDLINE: 75003702] ">Dotti 1979</a>) found no difference in mental state measured on the BPRS. </p> </section> <section id="CD000307-sec-0176"> <h5 class="title">1.6 Extrapyramidal adverse effects</h5> <p>The occurrence of tardive dyskinesia (long term) was not significantly different, although the quality of the evidence is very low and data were again from a single small study (<a href="./references#CD000307-bbs2-0026" title="JolleyAG , HirschSR , MorrisonE , McRinkA , WilsonL . Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ1990;301:837‐42. ">Jolley 1990</a>). </p> </section> </section> <section id="CD000307-sec-0177"> <h4 class="title">2. Fluphenazine decanoate versus oral neuroleptics</h4> <section id="CD000307-sec-0178"> <h5 class="title">2.1 Death</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0179"> <h5 class="title">2.2 Relapse</h5> <p>Very low quality evidence from six studies showed that medium‐term rates of relapse were not significantly different in the fluphenazine decanoate group (49%) compared with oral neuroleptics (42%). </p> </section> <section id="CD000307-sec-0180"> <h5 class="title">2.3 Clinically significant change in global state</h5> <p>One small study (<a href="./references#CD000307-bbs2-0067" title="SongY . A double‐blind control study on the effect of pipotiazine palmitate and fluphenazine decanoate in the treatment of schizophrenia [data not available]. Chinese Journal of Neurology and Psychiatry1993;26(3):137‐40. ">Song 1993</a>) found no difference in the number of participants showing a clinically significant change in global state. </p> </section> <section id="CD000307-sec-0181"> <h5 class="title">2.4 Hospital admission</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0182"> <h5 class="title">2.5 Leaving the study early</h5> <p>Low‐quality evidence showed no difference in the number of participants leaving the study early for fluphenazine decanoate (17%) versus oral neuroleptics (18%). </p> </section> <section id="CD000307-sec-0183"> <h5 class="title">2.6 Mental state</h5> <p>Very low quality evidence from one study (<a href="./references#CD000307-bbs2-0065" title="SimonP , FermanianJ , GinestetD , GoujetMA , Peron‐MagnanP . Standard and long‐acting depot neuroleptics in chronic schizophrenics. Archives of General Psychiatry1978;35:893‐7. ">Simon 1978</a>) found no difference in mental state measured on the BPRS. </p> </section> <section id="CD000307-sec-0184"> <h5 class="title">2.7 Extrapyramidal adverse effects</h5> <p>Three small studies showed that general extrapyramidal adverse effects were lower in the fluphenazine decanoate group (7%) compared to oral neuroleptics (14%). However, the quality of the evidence was judged to be very low, and there was no difference with longer‐term data. The outcome of 'needing additional anticholinergic drug' was equivocal over short‐, medium‐ and longer‐term, suggesting oral neuroleptics and fluphenazine decanoate are similar in their ability to induce movement disorders. Also, tardive dyskinesia was significantly lower for the fluphenazine decanoate group during medium‐term evaluation, but was not different to oral neuroleptics with longer‐term data. </p> </section> </section> <section id="CD000307-sec-0185"> <h4 class="title">3. Fluphenazine decanoate versus other depot antipsychotics</h4> <section id="CD000307-sec-0186"> <h5 class="title">3.1 Death</h5> <p>One study did report a death in fluphenazine decanoate treatment group, however, this did produce an effect with no significant differences between groups for death. </p> </section> <section id="CD000307-sec-0187"> <h5 class="title">3.2 Global state</h5> <p>Eleven studies reported equivocal data fro the outcome of 'relapse' at six months to one year. Other global state outcomes such as significant clinical improvement, clinical global impression, needing additional antipsychotics and 'not improved' were also equivocal. </p> </section> <section id="CD000307-sec-0188"> <h5 class="title">3.3 Leaving the study early</h5> <p>Fifteen included trials found people were no more likely to leave the study early if they were receiving fluphenazine decanoate or other depot antipsychotics. </p> </section> <section id="CD000307-sec-0189"> <h5 class="title">3.4 Behaviour</h5> <p>Only one study reported equivocal data.</p> </section> <section id="CD000307-sec-0190"> <h5 class="title">3.5 Mental state</h5> <p>Short‐ and medium‐term studies assessing mental state (BPRS endpoint scores) to significantly favour 'other depot neuroleptics' for the short term and medium term. Long‐term studies did not find such difference in mental state. One study reported on the outcome of depression; <a href="./references#CD000307-bbs2-0013" title="DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . How schizophrenic patients change during 3 years' treatment with depot neuroleptics. Acta Psychiatria Scandanavia1978;57:115‐23. DenckerSJ , FrankenbergK , LeppM , LindbergD , MalmU . Three years' maintenance neuroleptic treatment in schizophrenia ‐ before and beyond. Acta Psychiatria Scandinavica1978;57:103‐14. DenckerSJ , FrankenbergK , MalmU , ZellB . A controlled one‐year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Acta Psychiatria Scandinavica1973;241(Suppl):101‐18. ">Dencker 1973</a>, found no significant difference between fluphenazine decanoate and pipothiazine palmitate. </p> </section> <section id="CD000307-sec-0191"> <h5 class="title">3.6 Adverse effects</h5> <p>The occurrence of dyskinetic movements in general was the same across short‐, medium‐ and longer‐term studies. Outcomes such as dry mouth, tardive dyskinesia and parkinsonism were not significantly different between depot fluphenazine and other depot neuroleptics. When reporting blurred vision, the results of one medium‐term trial were not significant, but one longer‐term study, <a href="./references#CD000307-bbs2-0051" title="PintoR , BanerjeeA , GhoshN . A double‐blind comparison of flupenthixol decanoate and fluphenazine decanoate int he treatment of chronic schizophrenia. Acta Psychiatria Scandinavia1979;60:313‐22. ">Pinto 1979</a>, did report significant results favouring flupenthixol decanoate. General adverse effects (short‐term data) were reported by <a href="./references#CD000307-bbs2-0018" title="FrangosH , ZississNP , LeontopoulosI , DiamentasN , TsitouridisS , GavriilI , et al. Double blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. Acta Psychiatria Scandinavica1978;57:436‐46. ">Frangos 1978</a> and <a href="./references#CD000307-bbs2-0025" title="JavedMA , ChaudhryMR . Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Pakistan Journal of Clinical Psychiatry1991;1(2):69‐74. ">Javed 1991</a> and favoured other depot neuroleptics. However, medium‐term data were equivocal. </p> </section> </section> <section id="CD000307-sec-0192"> <h4 class="title">4. Fluphenazine decanoate versus fluphenazine enanthate</h4> <section id="CD000307-sec-0193"> <h5 class="title">4.1 Death</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0194"> <h5 class="title">4.2 Relapse</h5> <p>Very low quality evidence from only one small study (<a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a>) found no significant difference in the number of participants experiencing relapse in the medium term. Results were also equivocal for immediate‐ and short‐term studies. </p> </section> <section id="CD000307-sec-0195"> <h5 class="title">4.3 Clinically significant change in global state</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0196"> <h5 class="title">4.4 Hospital admission</h5> <p>No studies reported data for this outcome.</p> </section> <section id="CD000307-sec-0197"> <h5 class="title">4.5 Leaving the study early</h5> <p>No difference in the number of participants leaving the study early was found between fluphenazine decanoate (29%) and fluphenazine enanthate (12%), but this is based on one small study (<a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a>) and considered to be very low quality evidence. </p> </section> <section id="CD000307-sec-0198"> <h5 class="title">4.6 Mental state</h5> <p>BPRS data were only available from one small trial (<a href="./references#CD000307-bbs2-0041" title="MacCrimmonDJ , SaxenaB , FoleyP , GrofP . Fluphenazine decanoate and fluphenazine enanthate in the out‐patient management of chronic schizophrenia. Neuropsychobiology1978;4:360‐5. ">MacCrimmon 1978</a>). This study reported identical scores for both of the fluphenazine depots groups. </p> </section> <section id="CD000307-sec-0199"> <h5 class="title">4.7 Extrapyramidal adverse effects</h5> <p>Very low evidence from two very small studies showed that two preparations caused roughly equal incidences of general movement disorders. Results were also equivocal for parkinsonism, akathisia and needing additional anticholinergics in the short and immediate term. </p> </section> </section> </section> <section id="CD000307-sec-0200"> <h3 class="title" id="CD000307-sec-0200">Overall completeness and applicability of evidence</h3> <p>Trials were based mainly in the community, or combined both hospital and community settings. Ages ranged between 13 and 81 years, but most people were in the 18 to 65 age range. The duration of illness was long in most participants in the studies that reported this. Included trials were conducted around the world, although the majority (56) were based in North America and Europe and none were based in Australia or South America. There is a broad mixture of participants, settings and clinical applicability of the interventions which should increase generalisability.The dosages of fluphenazine decanoate and enanthate reflected current clinical practice. Outcomes were, however, limited. No trials reported data on service utilisation, hospital admission and economic outcomes. It is a shame that so few outcomes were included. </p> </section> <section id="CD000307-sec-0201"> <h3 class="title" id="CD000307-sec-0201">Quality of the evidence</h3> <p>The quality of the evidence is low to very low based on GRADE (<a href="./references#CD000307-bbs2-0330" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359‐83. ">Schünemann 2008</a>). Although all studies were reported as randomised, only five reported the method of randomisation and another three the method of allocation concealment. For the majority of studies the method of blinding was not reported despite most stating that they were double blind. In 83% of studies, the risk of bias for selective reporting was rated as high; many pre‐planned outcomes were not reported and continuous data were often reported as mean without standard deviation, only as P values, or graphically. Poor presentation of data meant that a lot of potentially informative data were lost. </p> </section> <section id="CD000307-sec-0202"> <h3 class="title" id="CD000307-sec-0202">Potential biases in the review process</h3> <p>A thorough search strategy was used in this review. There may still be gaps in the search strategy such as unpublished data (grey literature), which are difficult to obtain. Futhermore, when assessing the risk of bias of studies previously included in this review, we were unable to assess the risk of bias for one study in Italian. However, this study did not contribute to any outcomes in the 'Summary of findings' tables and therefore the omission of this one study did not affect the overall quality judgement. </p> <p>For most outcomes we are not able to tell if there was publication bias, as no more than 10 trials reported data for these, and a funnel plot could not be performed. For leaving the study early in the comparison of fluphenazine decanoate versus oral neuroleptics, there does appear to be publication bias, as the funnel plot indicates that larger trials have not been performed. </p> </section> <section id="CD000307-sec-0203"> <h3 class="title" id="CD000307-sec-0203">Agreements and disagreements with other studies or reviews</h3> <p>We do not know of any other systematic reviews on this topic.</p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000307-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS, outcome: 2.4 Leaving the study early." data-id="CD000307-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 FLUPHENAZINE DECANOATE versus ORAL NEUROLEPTICS, outcome: 2.4 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD000307-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000307-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000307-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 1 Death." data-id="CD000307-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 2 Global state: 1. Relapse." data-id="CD000307-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 2 Global state: 1. Relapse.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 3 Global state: 2. GAS (short term ‐ 6 weeks to 5 months) (high score = worse)." data-id="CD000307-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 3 Global state: 2. GAS (short term ‐ 6 weeks to 5 months) (high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 4 Leaving the study early." data-id="CD000307-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 4 Leaving the study early.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 5 Mental state: 1. BPRS (endpoint scores ‐ high score = worse)." data-id="CD000307-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 5 Mental state: 1. BPRS (endpoint scores ‐ high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 6 Mental state: 2. Depression (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 6 Mental state: 2. Depression (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 7 Adverse effects: 1. Movement disorders ‐ tardive dyskinesia (longer term ‐ more than 1 year)." data-id="CD000307-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 7 Adverse effects: 1. Movement disorders ‐ tardive dyskinesia (longer term ‐ more than 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 8 Adverse effects: 2. Toxicity." data-id="CD000307-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 FLUPHENAZINE DECANOATE vs PLACEBO, Outcome 8 Adverse effects: 2. Toxicity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 1 Global state: 1. No clinically important global change." data-id="CD000307-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 1 Global state: 1. No clinically important global change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 2 Global state: 2. Relapse." data-id="CD000307-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 2 Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 3 Global state: 3. Clinical Global Impression (short term ‐ 6 weeks to 5 months) (high score = worse)." data-id="CD000307-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 3 Global state: 3. Clinical Global Impression (short term ‐ 6 weeks to 5 months) (high score = worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 4 Leaving the study early." data-id="CD000307-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 4 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 5 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor)." data-id="CD000307-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 5 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0018"> <p> <div class="table" id="CD000307-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barnes 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barnes 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pimozide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 6 Behaviour: 2. skewed data (endpoint scores). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0018">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000307-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 7 Mental state: 1. BPRS ‐ endpoint scores (longer term ‐ more than 1 year) (high score = poor)." data-id="CD000307-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 7 Mental state: 1. BPRS ‐ endpoint scores (longer term ‐ more than 1 year) (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 8 Mental state: 2. Depression." data-id="CD000307-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 8 Mental state: 2. Depression. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 9 Adverse effects: 1a. Movement disorders ‐ general." data-id="CD000307-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 9 Adverse effects: 1a. Movement disorders ‐ general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10 Adverse effects: 1b. Movement disorders ‐ akathisia." data-id="CD000307-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 10 Adverse effects: 1b. Movement disorders ‐ akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11 Adverse effects: 1c. Movement disorders ‐ needing anticholinergic drugs." data-id="CD000307-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 11 Adverse effects: 1c. Movement disorders ‐ needing anticholinergic drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia." data-id="CD000307-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 12 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13 Adverse effects: 1e. Movement disorders ‐ tremor (longer term ‐ more than 1 year)." data-id="CD000307-fig-0025" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 13 Adverse effects: 1e. Movement disorders ‐ tremor (longer term ‐ more than 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14 Adverse effects: 1f. Movement disorders ‐ average score (Simpson &amp; Angus, 0 to 5 weeks, high = poor)." data-id="CD000307-fig-0026" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 14 Adverse effects: 1f. Movement disorders ‐ average score (Simpson &amp; Angus, 0 to 5 weeks, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15 Adverse effects: 2. Blurred vision ‐ medium term (6 months to 1 year)." data-id="CD000307-fig-0027" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 15 Adverse effects: 2. Blurred vision ‐ medium term (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16 Adverse effects: 3. Toxicity ‐ medium term (6 months to 1 year)." data-id="CD000307-fig-0028" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 16 Adverse effects: 3. Toxicity ‐ medium term (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17 Adverse effects: 4. General adverse effects." data-id="CD000307-fig-0029" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 17 Adverse effects: 4. General adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 18 SENSITIVITY ANALYSIS Global state: 2. Relapse." data-id="CD000307-fig-0030" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS, Outcome 18 SENSITIVITY ANALYSIS Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 1 Death." data-id="CD000307-fig-0031" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 2 Global state: 1. No clinically important global change." data-id="CD000307-fig-0032" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 2 Global state: 1. No clinically important global change. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 3 Global state: 2. Relapse." data-id="CD000307-fig-0033" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 3 Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 4 Global state: 3. Severly ill (medium term 6 months to 1 year)." data-id="CD000307-fig-0034" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 4 Global state: 3. Severly ill (medium term 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 5 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year)." data-id="CD000307-fig-0035" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 5 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0036"> <p> <div class="table" id="CD000307-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wistedt 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wistedt 1984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pipothiazine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 6 Global state: 5. Clinical Global Impression. (short term ‐ 6 weeks to 5 months) (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000307-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 7 Global state: 6. Clinical Global Impression. (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0037" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 7 Global state: 6. Clinical Global Impression. (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 8 Global state: 7. Clinical Global Impression ‐ not improved (high score = poor)." data-id="CD000307-fig-0038" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 8 Global state: 7. Clinical Global Impression ‐ not improved (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 9 Leaving the study early." data-id="CD000307-fig-0039" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 9 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor)." data-id="CD000307-fig-0040" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Mental state: 1. BPRS (endpoint scores ‐ high score = poor)." data-id="CD000307-fig-0041" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Mental state: 1. BPRS (endpoint scores ‐ high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year ‐ dichotomous data)." data-id="CD000307-fig-0042" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year ‐ dichotomous data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 13 Mental state: 3. Depression (6 months to 1 year)." data-id="CD000307-fig-0043" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 13 Mental state: 3. Depression (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0044"> <p> <div class="table" id="CD000307-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>SAPS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>SANS</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 14 Mental state: 4. SAPS and SANS (endpoint scores ‐ high score = poor) (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0044">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000307-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 15 Adverse effects: 1a. Movement disorders ‐ general." data-id="CD000307-fig-0045" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 15 Adverse effects: 1a. Movement disorders ‐ general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 16 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs." data-id="CD000307-fig-0046" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 16 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 17 Adverse effects: 1c. Movement disorders ‐ parkinsonism." data-id="CD000307-fig-0047" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 17 Adverse effects: 1c. Movement disorders ‐ parkinsonism. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 18 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia: longer term (more than 1 year)." data-id="CD000307-fig-0048" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 18 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia: longer term (more than 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 19 Adverse effects: 1e. Movement disorders ‐ tremor." data-id="CD000307-fig-0049" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 19 Adverse effects: 1e. Movement disorders ‐ tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0050"> <p> <div class="table" id="CD000307-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>TESS (high = poor)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>RSESE (high = poor)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ju 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pipothiazine palmitate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 20 Adverse effects: 1f. Movement disorders ‐ endpoint scores (short term ‐ 6 weeks to 5 months). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000307-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 21 Adverse effects: 2. Blurred vision." data-id="CD000307-fig-0051" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 21 Adverse effects: 2. Blurred vision. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 22 Adverse effects: 3. Dry mouth: longer term (more than 1 year)." data-id="CD000307-fig-0052" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 22 Adverse effects: 3. Dry mouth: longer term (more than 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 23 Adverse effects: 4. General adverse effects." data-id="CD000307-fig-0053" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 23 Adverse effects: 4. General adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-003-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-003-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 24 SENSITIVITY ANALYSIS Global state: 2. Relapse." data-id="CD000307-fig-0054" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3 FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS, Outcome 24 SENSITIVITY ANALYSIS Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-003-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 1 Global state: 1. Relapse (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0055" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 1 Global state: 1. Relapse (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 2 Global state: 2. Needing additional antispsychotic treatment (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0056" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 2 Global state: 2. Needing additional antispsychotic treatment (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 3 Global state: 3. Not improved (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0057" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 3 Global state: 3. Not improved (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 4 Leaving the study early (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0058" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 4 Leaving the study early (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 5 Mental state: BPRS endpoint scores (medium term ‐ 6 months to 1 year, high score = poor)." data-id="CD000307-fig-0059" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 5 Mental state: BPRS endpoint scores (medium term ‐ 6 months to 1 year, high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 6 Adverse effects: Movement disorders ‐ needing anticholinergic drugs (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0060" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD, Outcome 6 Adverse effects: Movement disorders ‐ needing anticholinergic drugs (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 1 Global state: Relapse." data-id="CD000307-fig-0061" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 1 Global state: Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 2 Leaving the study early." data-id="CD000307-fig-0062" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 2 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 3 Adverse effects: 1. Movement disorders (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0063" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 3 Adverse effects: 1. Movement disorders (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0064"> <p> <div class="table" id="CD000307-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kane 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate (low dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kane 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluphenazine decanoate (standard dose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD, Outcome 4 Adverse effects: 2. Continuous data ‐ skewed data (endpoint scores, high = poor). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0064">Navigate to figure in review</a></div> </div> <div class="figure" id="CD000307-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 FLUPHENAZINE ENANTHATE vs PLACEBO, Outcome 1 Adverse effects: Movement disorders ‐ general." data-id="CD000307-fig-0065" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 FLUPHENAZINE ENANTHATE vs PLACEBO, Outcome 1 Adverse effects: Movement disorders ‐ general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 1 Global state: No clinically important global change (immediate ‐ 0 to 5 weeks)." data-id="CD000307-fig-0066" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 1 Global state: No clinically important global change (immediate ‐ 0 to 5 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 2 Adverse effects: Movement disorders ‐ general." data-id="CD000307-fig-0067" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS, Outcome 2 Adverse effects: Movement disorders ‐ general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 1 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year)." data-id="CD000307-fig-0068" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 1 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 2 Global state: 2. Relapse." data-id="CD000307-fig-0069" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 2 Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 3 Leaving the study early." data-id="CD000307-fig-0070" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 3 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 4 Mental state: 1. BPRS ‐ endpoint scores (medium term ‐ 6 months to 1 year) (high score = poor)." data-id="CD000307-fig-0071" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 4 Mental state: 1. BPRS ‐ endpoint scores (medium term ‐ 6 months to 1 year) (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 5 Mental state: 2. Depression (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0072" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 5 Mental state: 2. Depression (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 6 Adverse effects: 1a. Movement disorders ‐ general (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0073" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 6 Adverse effects: 1a. Movement disorders ‐ general (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 7 Adverse effects: 1b. Movement disorders ‐ needing additional anticholinergic drugs." data-id="CD000307-fig-0074" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 7 Adverse effects: 1b. Movement disorders ‐ needing additional anticholinergic drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 8 Adverse effects: 1c. Movement disorders ‐ tardive dyskinesia: medium term (6 months to 1 year)." data-id="CD000307-fig-0075" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 8 Adverse effects: 1c. Movement disorders ‐ tardive dyskinesia: medium term (6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 9 Adverse effects: 1d. Movement disorders ‐ tremor (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0076" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.9</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 9 Adverse effects: 1d. Movement disorders ‐ tremor (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Adverse effects: 2. Blurred vision (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0077" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.10</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 10 Adverse effects: 2. Blurred vision (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-008-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-008-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Adverse effects: 3. Dry mouth (medium term ‐ 6 months to 1 year)." data-id="CD000307-fig-0078" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.11</div> <div class="figure-caption"> <p>Comparison 8 FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS, Outcome 11 Adverse effects: 3. Dry mouth (medium term ‐ 6 months to 1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-008-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 1 Global state: Relapse (short term ‐ 6 weeks to 5 months)." data-id="CD000307-fig-0079" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 1 Global state: Relapse (short term ‐ 6 weeks to 5 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 2 Leaving the study early (short term ‐ 6 weeks to 5 months)." data-id="CD000307-fig-0080" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE, Outcome 2 Leaving the study early (short term ‐ 6 weeks to 5 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 1 Global state: 1. Needing additional antipsychotic treatment." data-id="CD000307-fig-0081" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 1 Global state: 1. Needing additional antipsychotic treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 2 Global state: 2. Relapse." data-id="CD000307-fig-0082" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 2 Global state: 2. Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 3 Behavioiur: Leaving the study early." data-id="CD000307-fig-0083" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 3 Behavioiur: Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 4 Mental State: BPRS medium term (6 months to 1 year ‐ high score = poor)." data-id="CD000307-fig-0084" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 4 Mental State: BPRS medium term (6 months to 1 year ‐ high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 5 Adverse effects: 1a. Movement disorders ‐ general." data-id="CD000307-fig-0085" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 5 Adverse effects: 1a. Movement disorders ‐ general. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 6 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs." data-id="CD000307-fig-0086" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 6 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 7 Adverse effects: 1c. Movement disorders ‐ parkinsonism (short term ‐ 6 weeks to 5 months)." data-id="CD000307-fig-0087" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 7 Adverse effects: 1c. Movement disorders ‐ parkinsonism (short term ‐ 6 weeks to 5 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 8 Adverse effects: 1d. Movement disorders ‐ akathisia (Immediate ‐ 0 to 5 weeks)." data-id="CD000307-fig-0088" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 8 Adverse effects: 1d. Movement disorders ‐ akathisia (Immediate ‐ 0 to 5 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-010-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-010-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 9 Adverse effects: 2. General adverse effects (immediate ‐ 0 to 5 weeks)." data-id="CD000307-fig-0089" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10 FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE, Outcome 9 Adverse effects: 2. General adverse effects (immediate ‐ 0 to 5 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-010-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 1 Global state: 1. Relapse (1 year)." data-id="CD000307-fig-0090" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 1 Global state: 1. Relapse (1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 2 Leaving the study early (1 year)." data-id="CD000307-fig-0091" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 2 Leaving the study early (1 year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 3 Mental state: 1. BPRS ‐ endpoint scores (1 year) (high score = poor)." data-id="CD000307-fig-0092" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 3 Mental state: 1. BPRS ‐ endpoint scores (1 year) (high score = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 4 Adverse effects: 1. Movement disorders ‐ MPRC (1 year, high = poor)." data-id="CD000307-fig-0093" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 4 Adverse effects: 1. Movement disorders ‐ MPRC (1 year, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000307-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/urn:x-wiley:14651858:media:CD000307:CD000307-CMP-011-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_t/tCD000307-CMP-011-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 5 Quality of life: Quality of life scale (1 year) (high score = good)." data-id="CD000307-fig-0094" src="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11 FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS, Outcome 5 Quality of life: Quality of life scale (1 year) (high score = good). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/media/CDSR/CD000307/image_n/nCD000307-CMP-011-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000307-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation: randomised ‐ clearly described generation of sequence and concealment of allocation.<br/> Blindness: double ‐ described and tested.<br/> Duration: 12 months minimum. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diagnosis: schizophrenia (operational criteria).<br/> N = 300*<br/> Age: any.<br/> Gender: both.<br/> History: any. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Fluphenazine decanoate/enanthate: clinically acceptable dose. N = 150.</p> <p>2. Oral antipsychotic: clinically acceptable dose. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death and all causes of mortality**<br/> Clinical global state ‐ relapse**; clinically significant change in global state**; leaving the study early**<br/> Service utilisation outcomes ‐ hospital admission**, time in hospital.<br/> Adverse effects: extrapyramidal adverse effects**, other adverse effects.<br/> Economic outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* The number of participants needed to gain sufficient power to highlight about a 10% difference between groups for primary outcome depends on the primary outcome used and the prevalence/magnitude of this outcome. N = 300 is approximately the size of study to detect a 10% difference in improvement with 80% certainty. </p> <p>** Primary outcome</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design of future trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000307-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANOATE<br/> <b>Comparison:</b> PLACEBO </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PLACEBO</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANOATE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5</b> <br/> (0.25 to 99.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>673 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>418 per 1000</b> <br/> (162 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.62</b> <br/> (0.24 to 1.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinically significant change in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>185 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>241 per 1000</b> <br/> (143 to 406) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.3</b> <br/> (0.77 to 2.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> BPRS<br/> Follow‐up: 9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>2.03 lower</b> <br/> (4.51 lower to 0.45 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ tardive dyskinesia</b> <br/> Follow‐up: 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>852 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>707 per 1000</b> <br/> (528 to 946) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.62 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment and blinding.<br/> <sup>2</sup> Imprecision: very serious ‐ There were few participants and few events; the confidence intervals are wide.<br/> <sup>3</sup> Publication bias: strongly suspected ‐ Four studies or fewer reported data for this outcome.<br/> <sup>4</sup> Risk of bias: serious ‐ The studies had an unclear risk of bias for randomisation, allocation concealment and blinding of participants.<br/> <sup>5</sup> Inconsistency: very serious ‐ There is very high heterogeneity.<br/> <sup>6</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>7</sup> Risk of bias: very serious ‐ This study had a high risk of bias for incomplete outcome data, and an unclear risk of bias for randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with PLACEBO for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000307-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANOATE<br/> <b>Comparison:</b> ORAL NEUROLEPTICS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ORAL NEUROLEPTICS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANOATE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>423 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>618 per 1000</b> <br/> (317 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b> <br/> (0.75 to 2.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No clinically important global change</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>519 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>441 per 1000</b> <br/> (291 to 659) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.85</b> <br/> (0.56 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>184 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>177 per 1000</b> <br/> (134 to 230) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.73 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>937<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> BPRS endpoint score<br/> Follow‐up: (longer term ‐ more than 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0.75 lower</b> <br/> (5.75 lower to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ general</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>137 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>64 per 1000</b> <br/> (33 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.47</b> <br/> (0.24 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,5,9</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies also reported equivocal results for akathisia, needing anticholinergic drugs, tardive dyskinesia, tremor, and symptoms on the Simpson Angus scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding. One study had a high risk of bias for incomplete outcome data.<br/> <sup>2</sup> Inconsistency: serious ‐ There is high heterogeneity.<br/> <sup>3</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>4</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment, blinding and incomplete outcome data.<br/> <sup>5</sup> Publication bias: strongly suspected ‐ Three studies or fewer reported data for this outcome.<br/> <sup>6</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding, although one study had a low risk of bias for blinding of participants. One study had a high risk of bias for incomplete outcome data.<br/> <sup>7</sup> Publication bias: undetected ‐ It seems that larger trials have not been performed, see <a href="./full#CD000307-fig-0001">Figure 1</a>. </p> <p><sup>8</sup>Risk of bias: very serious ‐ This study had a high risk of bias for blinding as it is an open label study. It has an unclear risk of bias for randomisation and allocation concealment.<br/> <sup>9</sup> Risk of bias: serious ‐ Studies had an unclear risk of bias for randomisation, allocation concealment and blinding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">FLUPHENAZINE DECANOATE compared with ORAL NEUROLEPTICS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000307-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> hospital and community<br/> <b>Intervention:</b> FLUPHENAZINE DECANAOTE<br/> <b>Comparison:</b> FLUPHENAZINE ENANTHATE </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE ENANTHATE</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> FLUPHENAZINE DECANAOTE</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> <br/> (85 to 998) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/> (0.71 to 8.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinically significant change in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospital admission</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early</b> <br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>292 per 1000</b> <br/> (85 to 998) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.43</b> <br/> (0.71 to 8.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental State</b> <br/> BPRS<br/> Follow‐up: medium term (6 months to 1 year) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>0 higher</b> <br/> (3.93 lower to 3.93 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Extrapyramidal adverse effects ‐ general</b> <br/> Follow‐up: short term (6 weeks to 5 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>538 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>614 per 1000</b> <br/> (425 to 883) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.14</b> <br/> (0.79 to 1.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies also reported equivocal results for Parkinsonism, akathisia and needing anticholinergic drugs. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: serious ‐ This study had an unclear risk of bias for randomisation, allocation concealment and blinding.<br/> <sup>2</sup> Imprecision: very serious ‐ There were few participants and few events; the confidence intervals are wide.<br/> <sup>3</sup> Publication bias: strongly suspected ‐ Fewer than three studies reported data for this outcome.<br/> <sup>4</sup> Imprecision: serious ‐ There are wide confidence intervals.<br/> <sup>5</sup> Risk of bias: serious ‐ The studies had an unclear risk of bias for randomisation and blinding of outcome assessors. One was low risk of bias for allocation concealment and the other for blinding of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">FLUPHENAZINE DECANAOTE compared to FLUPHENAZINE ENANTHATE for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/full#CD000307-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 99.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.24, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.19, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. GAS (short term ‐ 6 weeks to 5 months) (high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [‐4.41, 11.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.24, 24.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.77, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.23, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1. BPRS (endpoint scores ‐ high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.03 [‐4.51, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Depression (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.45, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1. Movement disorders ‐ tardive dyskinesia (longer term ‐ more than 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2. Toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.65 [1.04, 56.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. No clinically important global change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.46, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.75, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.81, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Clinical Global Impression (short term ‐ 6 weeks to 5 months) (high score = worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐2.79, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 immediate (0‐5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.32, 8.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.73, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.61, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐6.92, 5.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Behaviour: 2. skewed data (endpoint scores) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 1. BPRS ‐ endpoint scores (longer term ‐ more than 1 year) (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.75 [‐5.75, 4.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2. Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.60, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.91, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1a. Movement disorders ‐ general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.24, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.4 [0.12, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 1b. Movement disorders ‐ akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.54 [1.25, 337.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1c. Movement disorders ‐ needing anticholinergic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.21, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.86, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.41, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 1e. Movement disorders ‐ tremor (longer term ‐ more than 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.26, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 1f. Movement disorders ‐ average score (Simpson &amp; Angus, 0 to 5 weeks, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.3 [0.01, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 2. Blurred vision ‐ medium term (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.75, 2.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 3. Toxicity ‐ medium term (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [1.14, 20.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 4. General adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [0.24, 92.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 SENSITIVITY ANALYSIS Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. No clinically important global change <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.97, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.89, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.96, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.27, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.77, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3. Severly ill (medium term 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.94, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 4. Needing additional antipsychotic treatment (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.14, 1.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 5. Clinical Global Impression. (short term ‐ 6 weeks to 5 months) (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Global state: 6. Clinical Global Impression. (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.41, 0.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Global state: 7. Clinical Global Impression ‐ not improved (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [0.53, 11.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.18, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.32, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.89, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 By more than 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Behaviour: 1. NOSIE‐30 ‐ endpoint scores (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.21 [‐10.85, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 1. BPRS (endpoint scores ‐ high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.86, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.10, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 longer term (more than one year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [‐2.32, 4.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state: 2. BPRS (endpoint scores 6 months to 1 year ‐ dichotomous data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.59, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental state: 3. Depression (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.81, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state: 4. SAPS and SANS (endpoint scores ‐ high score = poor) (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 SAPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 SANS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 1a. Movement disorders ‐ general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.91, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 immediate term (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.24, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.43, 9.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.86, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.76, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.96, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.93, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.86, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 1c. Movement disorders ‐ parkinsonism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.47, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.24, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.37, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.07, 16.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: 1d. Movement disorders ‐ tardive dyskinesia: longer term (more than 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.32, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: 1e. Movement disorders ‐ tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.76, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.73, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: 1f. Movement disorders ‐ endpoint scores (short term ‐ 6 weeks to 5 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 TESS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 RSESE (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 2. Blurred vision <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.44, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.88 [1.08, 294.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 3. Dry mouth: longer term (more than 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.38, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 4. General adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.07, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>249</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 SENSITIVITY ANALYSIS Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">FLUPHENAZINE DECANOATE vs OTHER DEPOT NEUROLEPTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Relapse (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.30, 14.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Needing additional antispsychotic treatment (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.45, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 3. Not improved (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 nurse rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.09, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 psychiatrist rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.77, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.6 [0.15, 2.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: BPRS endpoint scores (medium term ‐ 6 months to 1 year, high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐5.79, 5.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: Movement disorders ‐ needing anticholinergic drugs (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.45, 6.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ HIGH DOSE vs STANDARD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [0.77, 14.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.38, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 longer term (more than 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.33, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: 1. Movement disorders (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Tardive dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.10, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Needing anticholinergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.72, 9.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 2. Continuous data ‐ skewed data (endpoint scores, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs STANDARD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs PLACEBO</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse effects: Movement disorders ‐ general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Needing anticholinergic drugs (short term ‐ 6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.69 [0.58, 163.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs PLACEBO</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: No clinically important global change (immediate ‐ 0 to 5 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.27, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: Movement disorders ‐ general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 movement disorders: immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [0.53, 10.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 side effects: immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.81 [0.94, 8.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 parkinsonism: immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.56 [0.91, 47.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs ORAL NEUROLEPTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Needing additional antipsychotic treatment (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.24, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.66, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.66, 8.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. BPRS ‐ endpoint scores (medium term ‐ 6 months to 1 year) (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.34, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Depression (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.39, 124.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1a. Movement disorders ‐ general (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.75, 3.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1b. Movement disorders ‐ needing additional anticholinergic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.16, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.76, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1c. Movement disorders ‐ tardive dyskinesia: medium term (6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.46, 1.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 1d. Movement disorders ‐ tremor (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.82, 1.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 2. Blurred vision (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 68.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 3. Dry mouth (medium term ‐ 6 months to 1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.36, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">FLUPHENAZINE ENANTHATE vs OTHER DEPOT NEUROLEPTICS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Relapse (short term ‐ 6 weeks to 5 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.35 [2.28, 38.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early (short term ‐ 6 weeks to 5 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.66, 14.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">FLUPHENAZINE ENANTHATE ‐ DOSAGE STUDIES ‐ LOW DOSE vs INTERMEDIATE/HIGH DOSE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Needing additional antipsychotic treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.18, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 mediium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.15, 6.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.18, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.70, 7.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.71, 8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Behavioiur: Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.18, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.70, 7.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.71, 8.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental State: BPRS medium term (6 months to 1 year ‐ high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐3.93, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 1a. Movement disorders ‐ general <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.82, 8.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.79, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1b. Movement disorders ‐ needing anticholinergic drugs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 immediate (0 to 5 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.12, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 short term (6 weeks to 5 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 medium term (6 months to 1 year)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.57, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1c. Movement disorders ‐ parkinsonism (short term ‐ 6 weeks to 5 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.02, 8.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 1d. Movement disorders ‐ akathisia (Immediate ‐ 0 to 5 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.19 [0.82, 46.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2. General adverse effects (immediate ‐ 0 to 5 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000307-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Relapse (1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.55, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early (1 year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.46, 2.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. BPRS ‐ endpoint scores (1 year) (high score = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [‐1.16, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Thought disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐1.51, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1. Movement disorders ‐ MPRC (1 year, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Parkinsonian symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.3 [‐0.03, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.4 [‐1.77, 6.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life: Quality of life scale (1 year) (high score = good) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [‐9.68, 12.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">FLUPHENAZINE DECANOATE ‐ DOSAGE STUDIES ‐ 2 WEEKS vs 6 WEEKS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000307.pub2/references#CD000307-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000307.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000307-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000307-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD000307-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD000307-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000307\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000307\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000307\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000307\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000307\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=8ranHhTh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000307.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000307.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000307.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000307.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000307.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720222370"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000307.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720222374"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000307.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dfbe1cfa99377',t:'MTc0MDcyMDIyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 